Exact Mass: 418.3168

Exact Mass Matches: 418.3168

Found 500 metabolites which its exact mass value is equals to given mass value 418.3168, within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error 0.01 dalton.

3a,7a-Dihydroxy-5b-cholestan-26-al

6-[(2S,5R,9R,15R)-5,9-dihydroxy-2,15-dimethyltetracyclo[8.7.0.0²,⁷.0¹¹,¹⁵]heptadecan-14-yl]-2-methylheptanal

C27H46O3 (418.3447)


3alpha,7alpha-Dihydroxy-5beta-cholestan-26-al is an intermediate involved in bile acid biosynthesis, specifically in the synthesis of chenodeoxyglycocholate and lithocholate. Bile acids are steroid acids found predominantly in the bile of mammals. The distinction between different bile acids is minute, depending only on the presence or absence of hydroxyl groups on positions 3, 7, and 12. Bile acids are physiological detergents that facilitate excretion, absorption, and transport of fats and sterols in the intestine and liver. Bile acids are also steroidal amphipathic molecules derived from the catabolism of cholesterol. They modulate bile flow and lipid secretion, are essential for the absorption of dietary fats and vitamins, and have been implicated in the regulation of all the key enzymes involved in cholesterol homeostasis. Bile acids recirculate through the liver, bile ducts, small intestine and portal vein to form an enterohepatic circuit. They exist as anions at physiological pH and, consequently, require a carrier for transport across the membranes of the enterohepatic tissues. The unique detergent properties of bile acids are essential for the digestion and intestinal absorption of hydrophobic nutrients. Bile acids have potent toxic properties (e.g. membrane disruption) and there are a plethora of mechanisms to limit their accumulation in blood and tissues (PMID: 11316487, 16037564, 12576301, 11907135). 3alpha,7alpha-Dihydroxy-5beta-cholestan-26-al is an intermediate involved in bile acid biosynthesis, specifically in the synthesis of chenodeoxyglycocholate and lithocholate. Bile acids are steroid acids found predominantly in bile of mammals. The distinction between different bile acids is minute, depends only on presence or absence of hydroxyl groups on positions 3, 7, and 12. Bile acids are physiological detergents that facilitate excretion, absorption, and transport of fats and sterols in the intestine and liver. Bile acids are also steroidal amphipathic molecules derived from the catabolism of cholesterol. They modulate bile flow and lipid secretion, are essential for the absorption of dietary fats and vitamins, and have been implicated in the regulation of all the key enzymes involved in cholesterol homeostasis. Bile acids recirculate through the liver, bile ducts, small intestine and portal vein to form an enterohepatic circuit. They exist as anions at physiological pH and, consequently, require a carrier for transport across the membranes of the enterohepatic tissues. The unique detergent properties of bile acids are essential for the digestion and intestinal absorption of hydrophobic nutrients. Bile acids have potent toxic properties (e.g., membrane disruption) and there are a plethora of mechanisms to limit their accumulation in blood and tissues. (PMID: 11316487, 16037564, 12576301, 11907135) [HMDB]

   

7a,12a-Dihydroxy-5a-cholestan-3-one

7α,12α-Dihydroxy-5β-cholestan-3-one

C27H46O3 (418.3447)


   

17a,20a-Dihydroxycholesterol

(20R)-cholest-5-ene-3beta,17alpha,20-triol

C27H46O3 (418.3447)


   

20a,22b-Dihydroxycholesterol

(2R,3R)-2-[(1S,2R,10S,11S,14S,15S)-5-hydroxy-2,15-dimethyltetracyclo[8.7.0.0²,⁷.0¹¹,¹⁵]heptadec-7-en-14-yl]-6-methylheptane-2,3-diol

C27H46O3 (418.3447)


20alpha,22beta-Dihydroxycholesterol is an intermediate in C21-Steroid hormone metabolism. 20alpha,22beta-Dihydroxycholesterol is the 8th to last step in the synthesis of 3alpha,11beta,21-Trihydroxy-20-oxo-5beta-pregnan-18-al and is converted from 20alpha-Hydroxycholesterol via the enzyme cytochrome P450 (EC 1.14.15.6). It is then converted to Pregnenolone via the enzyme cytochrome P450 (EC 1.14.15.6). [HMDB] 20alpha,22beta-Dihydroxycholesterol is an intermediate in C21-Steroid hormone metabolism. 20alpha,22beta-Dihydroxycholesterol is the 8th to last step in the synthesis of 3alpha,11beta,21-Trihydroxy-20-oxo-5beta-pregnan-18-al and is converted from 20alpha-Hydroxycholesterol via the enzyme cytochrome P450 (EC 1.14.15.6). It is then converted to Pregnenolone via the enzyme cytochrome P450 (EC 1.14.15.6).

   

7-a,27-Dihydroxycholesterol

(1S,2R,5S,9S,10S,11S,14R,15R)-14-[(2R)-7-hydroxy-6-methylheptan-2-yl]-2,15-dimethyltetracyclo[8.7.0.0²,⁷.0¹¹,¹⁵]heptadec-7-ene-5,9-diol

C27H46O3 (418.3447)


7-a,27-dihydroxycholesterol is an intermediate in bile acid biosynthesis. The enzyme 27-Hydroxycholesterol 7alpha-monooxygenase [EC:1.14.13.60] catalyzes the production of this metabolite from 27-hydroxycholesterol. This enzyme reaction is irreversible and occurs in the endoplasmic reticulum. [HMDB] 7-a,27-dihydroxycholesterol is an intermediate in bile acid biosynthesis. The enzyme 27-Hydroxycholesterol 7alpha-monooxygenase [EC:1.14.13.60] catalyzes the production of this metabolite from 27-hydroxycholesterol. This enzyme reaction is irreversible and occurs in the endoplasmic reticulum.

   

8-apo-beta-Carotenol

8-apo-beta-caroten-8-ol

C30H42O (418.3235)


D020011 - Protective Agents > D000975 - Antioxidants > D002338 - Carotenoids

   

Diisononyl phthalate

1,2-bis(7-methyloctyl) benzene-1,2-dicarboxylate

C26H42O4 (418.3083)


   

(24S)-7alpha,24-Dihydroxycholesterol

(1S,2R,5S,9S,10S,11S,14R,15R)-14-[(2R,5S)-5-hydroxy-6-methylheptan-2-yl]-2,15-dimethyltetracyclo[8.7.0.0²,⁷.0¹¹,¹⁵]heptadec-7-ene-5,9-diol

C27H46O3 (418.3447)


This compound belongs to the family of Trihydroxy Bile Acids, Alcohols and Derivatives. These are prenol lipids structurally characterized by a bile acid or alcohol which bears three hydroxyl groups.

   

7-a,25-Dihydroxycholesterol

3beta,7alpha,25-Trihydroxycholest-5-ene

C27H46O3 (418.3447)


7α, 25-dihydroxycholesterol (7α,25-OHC) is a potent and selective agonist and endogenous ligand of the orphan GPCR receptor EBI2 (GPR183). 7α, 25-dihydroxycholesterol is highly potent at activating EBI2 (EC50=140 pM; Kd=450 pM). 7α, 25-dihydroxycholesterol can serve as a chemokine directing migration of B cells, T cells and dendritic cells[1][2].

   

7a,12a-Dihydroxy-5a-cholestan-3-one

(1S,2S,9R,11S,15R)-9,16-dihydroxy-2,15-dimethyl-14-(6-methylheptan-2-yl)tetracyclo[8.7.0.0²,⁷.0¹¹,¹⁵]heptadecan-5-one

C27H46O3 (418.3447)


7alpha,12alpha-Dihydroxy-5alpha-cholestan-3-one is an intermediate in bile acid biosynthesis. Bile acids are steroid acids found predominantly in the bile of mammals. The distinction between different bile acids is minute, depending only on the presence or absence of hydroxyl groups on positions 3, 7, and 12. Bile acids are physiological detergents that facilitate excretion, absorption, and transport of fats and sterols in the intestine and liver. Bile acids are also steroidal amphipathic molecules derived from the catabolism of cholesterol. They modulate bile flow and lipid secretion, are essential for the absorption of dietary fats and vitamins, and have been implicated in the regulation of all the key enzymes involved in cholesterol homeostasis. Bile acids recirculate through the liver, bile ducts, small intestine and portal vein to form an enterohepatic circuit. They exist as anions at physiological pH and, consequently, require a carrier for transport across the membranes of the enterohepatic tissues. The unique detergent properties of bile acids are essential for the digestion and intestinal absorption of hydrophobic nutrients. Bile acids have potent toxic properties (e.g. membrane disruption) and there are a plethora of mechanisms to limit their accumulation in blood and tissues (PMID: 11316487, 16037564, 12576301, 11907135). 7alpha,12alpha-Dihydroxy-5alpha-cholestan-3-one is an intermediate in bile acid biosynthesis. Bile acids are steroid acids found predominantly in bile of mammals. The distinction between different bile acids is minute, depends only on presence or absence of hydroxyl groups on positions 3, 7, and 12. Bile acids are physiological detergents that facilitate excretion, absorption, and transport of fats and sterols in the intestine and liver. Bile acids are also steroidal amphipathic molecules derived from the catabolism of cholesterol. They modulate bile flow and lipid secretion, are essential for the absorption of dietary fats and vitamins, and have been implicated in the regulation of all the key enzymes involved in cholesterol homeostasis. Bile acids recirculate through the liver, bile ducts, small intestine and portal vein to form an enterohepatic circuit. They exist as anions at physiological pH and, consequently, require a carrier for transport across the membranes of the enterohepatic tissues. The unique detergent properties of bile acids are essential for the digestion and intestinal absorption of hydrophobic nutrients. Bile acids have potent toxic properties (e.g., membrane disruption) and there are a plethora of mechanisms to limit their accumulation in blood and tissues. (PMID: 11316487, 16037564, 12576301, 11907135) [HMDB]

   

Palmitoyl glucuronide

(2S,3S,4S,5R,6R)-6-(hexadecyloxy)-3,4,5-trihydroxyoxane-2-carboxylic acid

C22H42O7 (418.293)


Palmitoyl glucuronide is a natural human metabolite of Palmitic acid generated in the liver by UDP glucuonyltransferase. Glucuronidation is used to assist in the excretion of toxic substances, drugs or other substances that cannot be used as an energy source. Glucuronic acid is attached via a glycosidic bond to the substance, and the resulting glucuronide, which has a much higher water solubility than the original substance, is eventually excreted by the kidneys. Palmitoyl glucuronide is a natural human metabolite of Palmitic acid generated in the liver by UDP glucuonyltransferase.

   

Simvastatin

2,2-dimethyl-1S,2,3R,7S,8S,8aR-hexahydro-3,7-dimethyl-8-[2-[(2R,4R)-tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl]ethyl]-1-naphthalenyl ester, butanoic acid

C25H38O5 (418.2719)


C - Cardiovascular system > C10 - Lipid modifying agents > C10A - Lipid modifying agents, plain > C10AA - Hmg coa reductase inhibitors D057847 - Lipid Regulating Agents > D000960 - Hypolipidemic Agents > D000924 - Anticholesteremic Agents D004791 - Enzyme Inhibitors > D019161 - Hydroxymethylglutaryl-CoA Reductase Inhibitors C78276 - Agent Affecting Digestive System or Metabolism > C29703 - Antilipidemic Agent COVID info from clinicaltrial, clinicaltrials, clinical trial, clinical trials C471 - Enzyme Inhibitor > C1655 - HMG-CoA Reductase Inhibitor D009676 - Noxae > D000963 - Antimetabolites Corona-virus Coronavirus SARS-CoV-2 COVID-19 SARS-CoV COVID19 SARS2 SARS CONFIDENCE standard compound; EAWAG_UCHEM_ID 3144 CONFIDENCE standard compound; INTERNAL_ID 1128

   

3alpha,12alpha-Dihydroxy-5beta-pregnan-20-one diacetate

3alpha,12alpha-Dihydroxy-5beta-pregnan-20-one diacetate

C25H38O5 (418.2719)


   

Simvastatin

2,2-Dimethylbutyric acid, 8-ester with (4R,6R)-6-(2-((1S,2S,6R,8S,8ar)-1,2,6,7,8,8a-hexahydro-8-hydroxy-2,6-dimethyl-1-naphthyl)ethyl)tetrahydro-4-hydroxy-2H-pyran-2-one

C25H38O5 (418.2719)


Simvastatin is a hypolipidemic drug belonging to the class of pharmaceuticals called statins. It is used to control hypercholesterolemia (elevated cholesterol levels) and to prevent cardiovascular disease. Simvastatin is a synthetic derivate of a fermentation product of Aspergillus terreus; Simvastatin is a powerful lipid-lowering drug that can decrease low density lipoprotein (LDL) levels by up to 50 percent. It is used in doses of 5 mg up to 80 mg. Higher doses (160 mg) have been found to be too toxic, while giving only minimal benefit in terms of lipid lowering. There is no real effect on HDL and triglyceride levels.; Simvastatin (INN) is a hypolipidemic drug belonging to the class of pharmaceuticals called statins. It is used to control hypercholesterolemia (elevated cholesterol levels) and to prevent cardiovascular disease. Simvastatin is a synthetic derivate of a fermentation product of Aspergillus terreus; The drug is the form of an inactive lactone that is hydrolized after ingestion to produce the active agent. It is a white, nonhygroscopic, crystalline powder that is practically insoluble in water, and freely soluble in chloroform, methanol and ethanol; Ezetimibe/simvastatin is a combination product to lower lipids and marketed as Vytorin. [HMDB] Simvastatin is a hypolipidemic drug belonging to the class of pharmaceuticals called statins. It is used to control hypercholesterolemia (elevated cholesterol levels) and to prevent cardiovascular disease. Simvastatin is a synthetic derivate of a fermentation product of Aspergillus terreus; Simvastatin is a powerful lipid-lowering drug that can decrease low density lipoprotein (LDL) levels by up to 50 percent. It is used in doses of 5 mg up to 80 mg. Higher doses (160 mg) have been found to be too toxic, while giving only minimal benefit in terms of lipid lowering. There is no real effect on HDL and triglyceride levels. Simvastatin (INN) is a hypolipidemic drug belonging to the class of pharmaceuticals called statins. It is used to control hypercholesterolemia (elevated cholesterol levels) and to prevent cardiovascular disease. Simvastatin is a synthetic derivate of a fermentation product of Aspergillus terreus; The drug is the form of an inactive lactone that is hydrolized after ingestion to produce the active agent. It is a white, nonhygroscopic, crystalline powder that is practically insoluble in water, and freely soluble in chloroform, methanol and ethanol; Ezetimibe/simvastatin is a combination product to lower lipids and marketed as Vytorin. C - Cardiovascular system > C10 - Lipid modifying agents > C10A - Lipid modifying agents, plain > C10AA - Hmg coa reductase inhibitors D057847 - Lipid Regulating Agents > D000960 - Hypolipidemic Agents > D000924 - Anticholesteremic Agents D004791 - Enzyme Inhibitors > D019161 - Hydroxymethylglutaryl-CoA Reductase Inhibitors C78276 - Agent Affecting Digestive System or Metabolism > C29703 - Antilipidemic Agent COVID info from clinicaltrial, clinicaltrials, clinical trial, clinical trials C471 - Enzyme Inhibitor > C1655 - HMG-CoA Reductase Inhibitor D009676 - Noxae > D000963 - Antimetabolites Simvastatin. CAS Common Chemistry. CAS, a division of the American Chemical Society, n.d. https://commonchemistry.cas.org/detail?cas_rn=79902-63-9 (retrieved 2024-10-09) (CAS RN: 79902-63-9). Licensed under the Attribution-Noncommercial 4.0 International License (CC BY-NC 4.0).

   

(24R)-Cholest-5-ene-3-beta,7-alpha,24-triol

(1S,2R,5S,9S,10S,11S,15R)-14-[(2R,5R)-5-hydroxy-6-methylheptan-2-yl]-2,15-dimethyltetracyclo[8.7.0.0²,⁷.0¹¹,¹⁵]heptadec-7-ene-5,9-diol

C27H46O3 (418.3447)


(24R)-Cholest-5-ene-3-beta,7-alpha,24-triol is a hydroxysterol and a bile acid intermediate. It is produced from the reaction of 24(R)-Hydroxycholesterol with the enzyme CYP39A, which is also known as 24-hydroxycholesterol 7alpha-hydroxylase (EC 1.14.13.99). This enzyme catalyzes the following reaction: (24R)-cholest-5-ene-3beta,24-diol + NADPH + H+ O2 = (24R)-cholest-5-ene-3beta,7alpha,24-triol + NADP+ + H2O. This leads to the 7-alpha hydroxylation of 24(R)-hydroxycholesterol. This enzyme can act on both the 24R and 24S isomers. [HMDB] (24R)-Cholest-5-ene-3-beta,7-alpha,24-triol is a hydroxysterol and a bile acid intermediate. It is produced from the reaction of 24(R)-Hydroxycholesterol with the enzyme CYP39A, which is also known as 24-hydroxycholesterol 7alpha-hydroxylase (EC 1.14.13.99). This enzyme catalyzes the following reaction: (24R)-cholest-5-ene-3beta,24-diol + NADPH + H+ O2 = (24R)-cholest-5-ene-3beta,7alpha,24-triol + NADP+ + H2O. This leads to the 7-alpha hydroxylation of 24(R)-hydroxycholesterol. This enzyme can act on both the 24R and 24S isomers.

   

Cavipetin D

(2E)-4-{[(2E,6E,10E,14E)-16-hydroxy-3,7,11,15-tetramethylhexadeca-2,6,10,14-tetraen-1-yl]oxy}-3-methyl-4-oxobut-2-enoic acid

C25H38O5 (418.2719)


Cavipetin D is found in mushrooms. Cavipetin D is a constituent of the edible mushroom (Boletinus cavipes) Constituent of the edible mushroom (Boletinus cavipes). Cavipetin D is found in mushrooms.

   

beta-Citraurinene

3,5,5-trimethyl-4-[(1E,3Z,5E,7E,9E,11Z,13E)-3,7,12,16-tetramethylheptadeca-1,3,5,7,9,11,13,15-octaen-1-yl]cyclohex-3-en-1-ol

C30H42O (418.3235)


beta-Citraurinene is found in citrus. beta-Citraurinene is a constituent of citrus peel Constituent of citrus peel. beta-Citraurinene is found in citrus.

   

Hexadecyl ferulate

Hexadecyl (2Z)-3-(4-hydroxy-3-methoxyphenyl)prop-2-enoic acid

C26H42O4 (418.3083)


Hexadecyl ferulate is found in potato. Hexadecyl ferulate is isolated from Ipomoea batatas (sweet potato). Isolated from Ipomoea batatas (sweet potato). Hexadecyl ferulate is found in root vegetables and potato.

   

7a,12a-Dihydroxy-5b-cholestan-3-one

(1S,2S,9R,11R,15R)-9,16-dihydroxy-2,15-dimethyl-14-(6-methylheptan-2-yl)tetracyclo[8.7.0.0²,⁷.0¹¹,¹⁵]heptadecan-5-one

C27H46O3 (418.3447)


7alpha,12alpha-Dihydroxy-5beta-cholestan-3-one is an intermediate in bile acid biosynthesis. Bile acids are steroid acids found predominantly in the bile of mammals. The distinction between different bile acids is minute, depending only on the presence or absence of hydroxyl groups on positions 3, 7, and 12. Bile acids are physiological detergents that facilitate excretion, absorption, and transport of fats and sterols in the intestine and liver. Bile acids are also steroidal amphipathic molecules derived from the catabolism of cholesterol. They modulate bile flow and lipid secretion, are essential for the absorption of dietary fats and vitamins, and have been implicated in the regulation of all the key enzymes involved in cholesterol homeostasis. Bile acids recirculate through the liver, bile ducts, small intestine and portal vein to form an enterohepatic circuit. They exist as anions at physiological pH and, consequently, require a carrier for transport across the membranes of the enterohepatic tissues. The unique detergent properties of bile acids are essential for the digestion and intestinal absorption of hydrophobic nutrients. Bile acids have potent toxic properties (e.g. membrane disruption) and there are a plethora of mechanisms to limit their accumulation in blood and tissues (PMID: 11316487, 16037564, 12576301, 11907135).

   

11'-Carboxy-alpha-chromanol

(4R,8S)-11-[(2R)-6-hydroxy-2,5,7,8-tetramethyl-3,4-dihydro-2H-1-benzopyran-2-yl]-4,8-dimethylundecanoic acid

C26H42O4 (418.3083)


11-carboxy-alpha-tocopherol is a dehydrogenation carboxylate product of 11-hydroxy-a-tocopherol by an unidentified microsomal enzyme(s) probably via an aldehyde intermediate. The tocopherols ( a-tocopherol , b-tocopherol ,r-tocopherol and d-tocopherol ) and their corresponding tocotrienols are synthesized by plants and have vitamin E antixoidant activity (see pathway vitamin E biosynthesis ). They differ in the number and location of methyl groups on the chromanol ring. The naturally occurring form of a-tocopherol is (2R,4R,8R)-a-tocopherol (synonym (R,R,R)-a-tocopherol). Synthetic a-tocopherols are a racemic mixture of eight different R and S stereoisomers. Only the 2R forms are recognized as meeting human requirements. The in vivo function of vitamin E is to scavenge peroxyl radicals via its phenolic (chromanol) hydroxyl group, thus protecting lipids against free radical-catalyzed peroxidation. The tocopheryl radical formed can then be reduced by reductants such as L-ascorbate. Other major products of a-tocopherol oxidation include α-tocopherylquinone and epoxy-a-tocopherols. The metabolites a-tocopheronic acid and its lactone, known as the Simon metabolites, are generally believed to be artefacts. In addition to these oxidation products, the other major class of tocopherol metabolites is the carboxyethyl-hydroxychromans.These metabolites are produced in significant amounts in response to excess vitamin E ingestion. Vitamin E is fat-soluble and its utilization requires intestinal fat absorption mechanisms. It is secreted from the intestine into the lymphatic system in chylomicrons which subsequently enter the plasma. Lipolysis of these chylomicrons can result in delivery of vitamin E to tissues, transfer to high-density lipoproteins (and subsequently to other lipoproteins via the phospholipid exchange protein), or retention in chylomicron remnants. These remnants are taken up by the liver. Natural (R,R,R)-α-tocopherol and synthetic 2R-α-tocopherols are then preferentially secreted from the liver into plasma as a result of the specificity of the α-tocopherol transfer protein. This protein, along with the metabolism of excess vitamin E in the liver and excretion into urine and bile, mediate the supply of a-tocopherol in plasma and tissues. 11-carboxy-alpha-tocopherol is a dehydrogenation carboxylate product of 11-hydroxy-a-tocopherol by an unidentified microsomal enzyme(s) probably via an aldehyde intermediate

   

7alpha,24-dihydroxy-5beta-cholestan-3-one

(1S,2S,7R,9R,10R,11S,14R,15R)-9-hydroxy-14-[(2R)-5-hydroxy-6-methylheptan-2-yl]-2,15-dimethyltetracyclo[8.7.0.0^{2,7}.0^{11,15}]heptadecan-5-one

C27H46O3 (418.3447)


7alpha,24-dihydroxy-5beta-cholestan-3-one is also known as 5beta-Cholestan-7alpha,24-diol-3-one. 7alpha,24-dihydroxy-5beta-cholestan-3-one is considered to be practically insoluble (in water) and basic. 7alpha,24-dihydroxy-5beta-cholestan-3-one is a bile acid lipid molecule

   

7alpha,26-dihydroxy-5beta-cholestan-3-one

(1S,2S,7R,9R,10R,11S,14R,15R)-9-hydroxy-14-[(2R)-7-hydroxy-6-methylheptan-2-yl]-2,15-dimethyltetracyclo[8.7.0.0^{2,7}.0^{11,15}]heptadecan-5-one

C27H46O3 (418.3447)


7alpha,26-dihydroxy-5beta-cholestan-3-one is also known as 5beta-Cholestan-7alpha,26-diol-3-one. 7alpha,26-dihydroxy-5beta-cholestan-3-one is considered to be practically insoluble (in water) and relatively neutral. 7alpha,26-dihydroxy-5beta-cholestan-3-one is a bile acid lipid molecule

   

(25R)-4beta,26-dihydroxycholesterol

(1S,2R,5S,6R,10S,11S,14R,15R)-14-[(2R,6R)-7-hydroxy-6-methylheptan-2-yl]-2,15-dimethyltetracyclo[8.7.0.0^{2,7}.0^{11,15}]heptadec-7-ene-5,6-diol

C27H46O3 (418.3447)


(25R)-4beta,26-dihydroxycholesterol is also known as (3beta,4beta,25R)-Cholest-5-ene-3,4,26-triol. (25R)-4beta,26-dihydroxycholesterol is considered to be practically insoluble (in water) and relatively neutral

   

4beta,7alpha-dihydroxycholesterol

(1S,2R,5S,6R,9S,10S,11S,14R,15R)-2,15-dimethyl-14-[(2R)-6-methylheptan-2-yl]tetracyclo[8.7.0.0^{2,7}.0^{11,15}]heptadec-7-ene-5,6,9-triol

C27H46O3 (418.3447)


4beta,7alpha-dihydroxycholesterol is also known as (3beta,4beta,7alpha)-Cholest-5-ene-3,4,7-triol. 4beta,7alpha-dihydroxycholesterol is considered to be practically insoluble (in water) and relatively neutral

   

4beta,24S-dihydroxycholesterol

(1S,2R,5S,6R,10S,11S,14R,15R)-14-[(2R,5S)-5-hydroxy-6-methylheptan-2-yl]-2,15-dimethyltetracyclo[8.7.0.0^{2,7}.0^{11,15}]heptadec-7-ene-5,6-diol

C27H46O3 (418.3447)


4beta,24S-dihydroxycholesterol is also known as (3beta,4beta,24S)-Cholest-5-ene-3,4,24-triol. 4beta,24S-dihydroxycholesterol is considered to be practically insoluble (in water) and relatively neutral

   

N-Arachidonoyl Asparagine

3-(C-Hydroxycarbonimidoyl)-2-[(1-hydroxyicosa-5,8,11,14-tetraen-1-ylidene)amino]propanoate

C24H38N2O4 (418.2831)


N-arachidonoyl asparagine belongs to the class of compounds known as N-acylamides. These are molecules characterized by a fatty acyl group linked to a primary amine by an amide bond. More specifically, it is an Arachidonic acid amide of Asparagine. It is believed that there are more than 800 types of N-acylamides in the human body. N-acylamides fall into several categories: amino acid conjugates (e.g., those acyl amides conjugated with amino acids), neurotransmitter conjugates (e.g., those acylamides conjugated with neurotransmitters), ethanolamine conjugates (e.g., those acylamides conjugated to ethanolamine), and taurine conjugates (e.g., those acyamides conjugated to taurine). N-Arachidonoyl Asparagine is an amino acid conjugate. N-acylamides can be classified into 9 different categories depending on the size of their acyl-group: 1) short-chain N-acylamides; 2) medium-chain N-acylamides; 3) long-chain N-acylamides; and 4) very long-chain N-acylamides; 5) hydroxy N-acylamides; 6) branched chain N-acylamides; 7) unsaturated N-acylamides; 8) dicarboxylic N-acylamides and 9) miscellaneous N-acylamides. N-Arachidonoyl Asparagine is therefore classified as a long chain N-acylamide. N-acyl amides have a variety of signaling functions in physiology, including in cardiovascular activity, metabolic homeostasis, memory, cognition, pain, motor control and others (PMID: 15655504). N-acyl amides have also been shown to play a role in cell migration, inflammation and certain pathological conditions such as diabetes, cancer, neurodegenerative disease, and obesity (PMID: 23144998; PMID: 25136293; PMID: 28854168).N-acyl amides can be synthesized both endogenously and by gut microbiota (PMID: 28854168). N-acylamides can be biosynthesized via different routes, depending on the parent amine group. N-acyl ethanolamines (NAEs) are formed via the hydrolysis of an unusual phospholipid precursor, N-acyl-phosphatidylethanolamine (NAPE), by a specific phospholipase D. N-acyl amino acids are synthesized via a circulating peptidase M20 domain containing 1 (PM20D1), which can catalyze the bidirectional the condensation and hydrolysis of a variety of N-acyl amino acids. The degradation of N-acylamides is largely mediated by an enzyme called fatty acid amide hydrolase (FAAH), which catalyzes the hydrolysis of N-acylamides into fatty acids and the biogenic amines. Many N-acylamides are involved in lipid signaling system through interactions with transient receptor potential channels (TRP). TRP channel proteins interact with N-acyl amides such as N-arachidonoyl ethanolamide (Anandamide), N-arachidonoyl dopamine and others in an opportunistic fashion (PMID: 23178153). This signaling system has been shown to play a role in the physiological processes involved in inflammation (PMID: 25136293). Other N-acyl amides, including N-oleoyl-glutamine, have also been characterized as TRP channel antagonists (PMID: 29967167). N-acylamides have also been shown to have G-protein-coupled receptors (GPCRs) binding activity (PMID: 28854168). The study of N-acylamides is an active area of research and it is likely that many novel N-acylamides will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered for these molecules.

   

(1R)-5-[2-[(1S,7As)-1-[(1S)-1-(3-hydroxy-3-methylbutoxy)ethyl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]-4-methylidenecyclohexane-1,3-diol

(1R)-5-[2-[(1S,7As)-1-[(1S)-1-(3-hydroxy-3-methylbutoxy)ethyl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]-4-methylidenecyclohexane-1,3-diol

C26H42O4 (418.3083)


   

7-Hydroperoxycholesterol

9-hydroperoxy-2,15-dimethyl-14-(6-methylheptan-2-yl)tetracyclo[8.7.0.0²,⁷.0¹¹,¹⁵]heptadec-7-en-5-ol

C27H46O3 (418.3447)


   

Cholesterol-5beta-hydroperoxide

5-Hydroperoxy-10,13-dimethyl-17-(6-methylheptan-2-yl)-1,2,3,4,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-3-ol

C27H46O3 (418.3447)


   

Dinonyl phthalate

1,2-Dinonyl benzene-1,2-dicarboxylic acid

C26H42O4 (418.3083)


   

(1R,3S,7R,8R,8As)-8-{2-[(2R,4S)-4-hydroxy-6-oxooxan-2-yl]ethyl}-3,7-dimethyl-1,2,3,7,8,8a-hexahydronaphthalen-1-yl 2,2-dimethylbutanoate

(1R,3S,7R,8R,8As)-8-{2-[(2R,4S)-4-hydroxy-6-oxooxan-2-yl]ethyl}-3,7-dimethyl-1,2,3,7,8,8a-hexahydronaphthalen-1-yl 2,2-dimethylbutanoate

C25H38O5 (418.2719)


Simvastatin is a hypolipidemic drug belonging to the class of pharmaceuticals called statins. It is used to control hypercholesterolemia (elevated cholesterol levels) and to prevent cardiovascular disease. Simvastatin is a synthetic derivate of a fermentation product of Aspergillus terreus; Simvastatin is a powerful lipid-lowering drug that can decrease low density lipoprotein (LDL) levels by up to 50 percent. It is used in doses of 5 mg up to 80 mg. Higher doses (160 mg) have been found to be too toxic, while giving only minimal benefit in terms of lipid lowering. There is no real effect on HDL and triglyceride levels.; Simvastatin (INN) is a hypolipidemic drug belonging to the class of pharmaceuticals called statins. It is used to control hypercholesterolemia (elevated cholesterol levels) and to prevent cardiovascular disease. Simvastatin is a synthetic derivate of a fermentation product of Aspergillus terreus; The drug is the form of an inactive lactone that is hydrolized after ingestion to produce the active agent. It is a white, nonhygroscopic, crystalline powder that is practically insoluble in water, and freely soluble in chloroform, methanol and ethanol; Ezetimibe/simvastatin is a combination product to lower lipids and marketed as Vytorin. [HMDB]

   

Valbenazine

L-Valine, (2R,3R,11bR)-1,3,4,6,7,11b-hexahydro-9,10-dimethoxy-3-(2-methylpropyl)-2H-benzo[a]quinolizin-2-yl ester;L-Valine, (2R,3R,11bR)-1,3,4,6,7,11b-hexahydro-9,10-dimethoxy-3-(2-methylpropyl)-2H-benzo[a]quinolizin-2-yl ester

C24H38N2O4 (418.2831)


   

MG(22:6(5Z,7Z,10Z,13Z,16Z,19Z)-OH(4)/0:0/0:0)

(2S)-2,3-Dihydroxypropyl (7Z,10Z,13Z,16Z,19Z)-4-hydroxydocosa-5,7,10,13,16,19-hexaenoic acid

C25H38O5 (418.2719)


MG(22:6(5Z,7Z,10Z,13Z,16Z,19Z)-OH(4)/0:0/0:0) is an oxidized monoacyglycerol (MG). Oxidized monoacyglycerols are glycerolipids in which the fatty acyl chain has undergone oxidation. As all oxidized lipids, oxidized monoacyglycerols belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with other lipids, monoacyglycerols can be substituted by different fatty acids, with varying lengths, saturation and degrees of oxidation attached at the C-1, C-2 and C-3 positions. Lipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with lipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized lipids is continually in flux, owing to lipid degradation and the continuous lipid remodeling that occurs while these molecules are in membranes. Oxidized MGs can be synthesized via three different routes. In one route, the oxidized MG is synthetized de novo following the same mechanisms as for MGs but incorporating an oxidized acyl chain (PMID: 33329396). An alternative is the transacylation of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the MG backbone, mainly through the action of LOX (PMID: 33329396).

   

MG(22:6(4Z,8Z,10Z,13Z,16Z,19Z)-OH(7)/0:0/0:0)

(2S)-2,3-Dihydroxypropyl (4Z,8Z,10Z,13Z,16Z,19Z)-7-hydroxydocosa-4,8,10,13,16,19-hexaenoic acid

C25H38O5 (418.2719)


MG(22:6(4Z,8Z,10Z,13Z,16Z,19Z)-OH(7)/0:0/0:0) is an oxidized monoacyglycerol (MG). Oxidized monoacyglycerols are glycerolipids in which the fatty acyl chain has undergone oxidation. As all oxidized lipids, oxidized monoacyglycerols belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with other lipids, monoacyglycerols can be substituted by different fatty acids, with varying lengths, saturation and degrees of oxidation attached at the C-1, C-2 and C-3 positions. Lipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with lipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized lipids is continually in flux, owing to lipid degradation and the continuous lipid remodeling that occurs while these molecules are in membranes. Oxidized MGs can be synthesized via three different routes. In one route, the oxidized MG is synthetized de novo following the same mechanisms as for MGs but incorporating an oxidized acyl chain (PMID: 33329396). An alternative is the transacylation of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the MG backbone, mainly through the action of LOX (PMID: 33329396).

   

MG(22:6(4Z,7Z,10Z,12E,16Z,19Z)-OH(14)/0:0/0:0)

(2S)-2,3-dihydroxypropyl (4Z,7Z,10Z,12E,16Z,19Z)-14-hydroxydocosa-4,7,10,12,16,19-hexaenoate

C25H38O5 (418.2719)


MG(22:6(4Z,7Z,10Z,12E,16Z,19Z)-OH(14)/0:0/0:0) is an oxidized monoacyglycerol (MG). Oxidized monoacyglycerols are glycerolipids in which the fatty acyl chain has undergone oxidation. As all oxidized lipids, oxidized monoacyglycerols belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with other lipids, monoacyglycerols can be substituted by different fatty acids, with varying lengths, saturation and degrees of oxidation attached at the C-1, C-2 and C-3 positions. Lipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with lipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized lipids is continually in flux, owing to lipid degradation and the continuous lipid remodeling that occurs while these molecules are in membranes. Oxidized MGs can be synthesized via three different routes. In one route, the oxidized MG is synthetized de novo following the same mechanisms as for MGs but incorporating an oxidized acyl chain (PMID: 33329396). An alternative is the transacylation of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the MG backbone, mainly through the action of LOX (PMID: 33329396).

   

MG(22:6(4Z,7Z,10Z,13E,15E,19Z)-OH(17)/0:0/0:0)

(2S)-2,3-Dihydroxypropyl (4Z,7Z,10Z,13E,15E,19Z)-17-hydroxydocosa-4,7,10,13,15,19-hexaenoic acid

C25H38O5 (418.2719)


MG(22:6(4Z,7Z,10Z,13E,15E,19Z)-OH(17)/0:0/0:0) is an oxidized monoacyglycerol (MG). Oxidized monoacyglycerols are glycerolipids in which the fatty acyl chain has undergone oxidation. As all oxidized lipids, oxidized monoacyglycerols belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with other lipids, monoacyglycerols can be substituted by different fatty acids, with varying lengths, saturation and degrees of oxidation attached at the C-1, C-2 and C-3 positions. Lipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with lipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized lipids is continually in flux, owing to lipid degradation and the continuous lipid remodeling that occurs while these molecules are in membranes. Oxidized MGs can be synthesized via three different routes. In one route, the oxidized MG is synthetized de novo following the same mechanisms as for MGs but incorporating an oxidized acyl chain (PMID: 33329396). An alternative is the transacylation of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the MG backbone, mainly through the action of LOX (PMID: 33329396).

   

MG(22:5(4Z,7Z,10Z,13Z,19Z)-O(16,17)/0:0/0:0)

(2S)-2,3-Dihydroxypropyl (4Z,7Z,10Z,13Z)-15-{3-[(2Z)-pent-2-en-1-yl]oxiran-2-yl}pentadeca-4,7,10,13-tetraenoic acid

C25H38O5 (418.2719)


MG(22:5(4Z,7Z,10Z,13Z,19Z)-O(16,17)/0:0/0:0) is an oxidized monoacyglycerol (MG). Oxidized monoacyglycerols are glycerolipids in which the fatty acyl chain has undergone oxidation. As all oxidized lipids, oxidized monoacyglycerols belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with other lipids, monoacyglycerols can be substituted by different fatty acids, with varying lengths, saturation and degrees of oxidation attached at the C-1, C-2 and C-3 positions. Lipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with lipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized lipids is continually in flux, owing to lipid degradation and the continuous lipid remodeling that occurs while these molecules are in membranes. Oxidized MGs can be synthesized via three different routes. In one route, the oxidized MG is synthetized de novo following the same mechanisms as for MGs but incorporating an oxidized acyl chain (PMID: 33329396). An alternative is the transacylation of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the MG backbone, mainly through the action of LOX (PMID: 33329396).

   

MG(0:0/22:6(5Z,7Z,10Z,13Z,16Z,19Z)-OH(4)/0:0)

1,3-Dihydroxypropan-2-yl (7Z,10Z,13Z,16Z,19Z)-4-hydroxydocosa-5,7,10,13,16,19-hexaenoic acid

C25H38O5 (418.2719)


MG(0:0/22:6(5Z,7Z,10Z,13Z,16Z,19Z)-OH(4)/0:0) is an oxidized monoacyglycerol (MG). Oxidized monoacyglycerols are glycerolipids in which the fatty acyl chain has undergone oxidation. As all oxidized lipids, oxidized monoacyglycerols belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with other lipids, monoacyglycerols can be substituted by different fatty acids, with varying lengths, saturation and degrees of oxidation attached at the C-1, C-2 and C-3 positions. Lipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with lipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized lipids is continually in flux, owing to lipid degradation and the continuous lipid remodeling that occurs while these molecules are in membranes. Oxidized MGs can be synthesized via three different routes. In one route, the oxidized MG is synthetized de novo following the same mechanisms as for MGs but incorporating an oxidized acyl chain (PMID: 33329396). An alternative is the transacylation of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the MG backbone, mainly through the action of LOX (PMID: 33329396).

   

MG(0:0/22:6(4Z,8Z,10Z,13Z,16Z,19Z)-OH(7)/0:0)

1,3-Dihydroxypropan-2-yl (4Z,8Z,10Z,13Z,16Z,19Z)-7-hydroxydocosa-4,8,10,13,16,19-hexaenoic acid

C25H38O5 (418.2719)


MG(0:0/22:6(4Z,8Z,10Z,13Z,16Z,19Z)-OH(7)/0:0) is an oxidized monoacyglycerol (MG). Oxidized monoacyglycerols are glycerolipids in which the fatty acyl chain has undergone oxidation. As all oxidized lipids, oxidized monoacyglycerols belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with other lipids, monoacyglycerols can be substituted by different fatty acids, with varying lengths, saturation and degrees of oxidation attached at the C-1, C-2 and C-3 positions. Lipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with lipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized lipids is continually in flux, owing to lipid degradation and the continuous lipid remodeling that occurs while these molecules are in membranes. Oxidized MGs can be synthesized via three different routes. In one route, the oxidized MG is synthetized de novo following the same mechanisms as for MGs but incorporating an oxidized acyl chain (PMID: 33329396). An alternative is the transacylation of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the MG backbone, mainly through the action of LOX (PMID: 33329396).

   

MG(0:0/22:6(4Z,7Z,10Z,12E,16Z,19Z)-OH(14)/0:0)

1,3-Dihydroxypropan-2-yl (4Z,7Z,10Z,16Z,19Z)-14-hydroxydocosa-4,7,10,12,16,19-hexaenoic acid

C25H38O5 (418.2719)


MG(0:0/22:6(4Z,7Z,10Z,12E,16Z,19Z)-OH(14)/0:0) is an oxidized monoacyglycerol (MG). Oxidized monoacyglycerols are glycerolipids in which the fatty acyl chain has undergone oxidation. As all oxidized lipids, oxidized monoacyglycerols belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with other lipids, monoacyglycerols can be substituted by different fatty acids, with varying lengths, saturation and degrees of oxidation attached at the C-1, C-2 and C-3 positions. Lipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with lipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized lipids is continually in flux, owing to lipid degradation and the continuous lipid remodeling that occurs while these molecules are in membranes. Oxidized MGs can be synthesized via three different routes. In one route, the oxidized MG is synthetized de novo following the same mechanisms as for MGs but incorporating an oxidized acyl chain (PMID: 33329396). An alternative is the transacylation of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the MG backbone, mainly through the action of LOX (PMID: 33329396).

   

MG(0:0/22:6(4Z,7Z,10Z,13E,15E,19Z)-OH(17)/0:0)

1,3-Dihydroxypropan-2-yl (4Z,7Z,10Z,13E,15E,19Z)-17-hydroxydocosa-4,7,10,13,15,19-hexaenoic acid

C25H38O5 (418.2719)


MG(0:0/22:6(4Z,7Z,10Z,13E,15E,19Z)-OH(17)/0:0) is an oxidized monoacyglycerol (MG). Oxidized monoacyglycerols are glycerolipids in which the fatty acyl chain has undergone oxidation. As all oxidized lipids, oxidized monoacyglycerols belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with other lipids, monoacyglycerols can be substituted by different fatty acids, with varying lengths, saturation and degrees of oxidation attached at the C-1, C-2 and C-3 positions. Lipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with lipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized lipids is continually in flux, owing to lipid degradation and the continuous lipid remodeling that occurs while these molecules are in membranes. Oxidized MGs can be synthesized via three different routes. In one route, the oxidized MG is synthetized de novo following the same mechanisms as for MGs but incorporating an oxidized acyl chain (PMID: 33329396). An alternative is the transacylation of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the MG backbone, mainly through the action of LOX (PMID: 33329396).

   

MG(0:0/22:5(4Z,7Z,10Z,13Z,19Z)-O(16,17)/0:0)

1,3-Dihydroxypropan-2-yl (4Z,7Z,10Z,13Z)-15-{3-[(2Z)-pent-2-en-1-yl]oxiran-2-yl}pentadeca-4,7,10,13-tetraenoic acid

C25H38O5 (418.2719)


MG(0:0/22:5(4Z,7Z,10Z,13Z,19Z)-O(16,17)/0:0) is an oxidized monoacyglycerol (MG). Oxidized monoacyglycerols are glycerolipids in which the fatty acyl chain has undergone oxidation. As all oxidized lipids, oxidized monoacyglycerols belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with other lipids, monoacyglycerols can be substituted by different fatty acids, with varying lengths, saturation and degrees of oxidation attached at the C-1, C-2 and C-3 positions. Lipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with lipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized lipids is continually in flux, owing to lipid degradation and the continuous lipid remodeling that occurs while these molecules are in membranes. Oxidized MGs can be synthesized via three different routes. In one route, the oxidized MG is synthetized de novo following the same mechanisms as for MGs but incorporating an oxidized acyl chain (PMID: 33329396). An alternative is the transacylation of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the MG backbone, mainly through the action of LOX (PMID: 33329396).

   

Furost-5-ene-3beta,22,26-triol

(6R,7S,9S,13R,16S)-6-(4-hydroxybutyl)-7,9,13-trimethyl-5-oxapentacyclo[10.8.0.0²,⁹.0⁴,⁸.0¹³,¹⁸]icos-18-ene-6,16-diol

C26H42O4 (418.3083)


Furost-5-ene-3beta,22,26-triol is practically insoluble (in water) and a very weakly acidic compound (based on its pKa). Furost-5-ene-3beta,22,26-triol can be found in fenugreek, which makes furost-5-ene-3beta,22,26-triol a potential biomarker for the consumption of this food product.

   

8'-Apo-b-caroten-8'-ol

(2E,4E,6E,8E,10E,12E,14Z,16E)-2,6,11,15-tetramethyl-17-(2,6,6-trimethylcyclohex-1-en-1-yl)heptadeca-2,4,6,8,10,12,14,16-octaen-1-ol

C30H42O (418.3235)


8-apo-b-caroten-8-ol is a member of the class of compounds known as triterpenoids. Triterpenoids are terpene molecules containing six isoprene units. 8-apo-b-caroten-8-ol is practically insoluble (in water) and an extremely weak acidic compound (based on its pKa). 8-apo-b-caroten-8-ol can be found in mandarin orange (clementine, tangerine), which makes 8-apo-b-caroten-8-ol a potential biomarker for the consumption of this food product.

   

4-Hydroxy-4,4-diaponeurosporene

7,8-Dihydro-4,4-diapo-psi,psi-caroten-4-ol

C30H42O (418.3235)


   
   

Aculeatin D

Aculeatin D

C26H42O4 (418.3083)


   

7beta-Hydroperoxycholesterol

7beta-Hydroperoxycholesterol

C27H46O3 (418.3447)


   
   

Boneratamide B methyl ester

(+)-Boneratamide B methyl ester

C24H38N2O4 (418.2831)


   

Griffinisterone I

Griffinisterone I

C27H46O3 (418.3447)


   

22,26-dihydroxycholesterol

22,26-dihydroxycholesterol

C27H46O3 (418.3447)


   

Boneratamide C methyl ester

(+)-Boneratamide C methyl ester

C24H38N2O4 (418.2831)


   

hydroxyheneicosenylresorcinol

hydroxyheneicosenylresorcinol

C27H46O3 (418.3447)


   

SCHEMBL17867454

SCHEMBL17867454

C30H42O (418.3235)


   

3beta,11-dihydroxy-9,11-secocholest-5-en-9-one|3beta-3,11-Dihydroxy-9,11-secocholest-5-en-9-one

3beta,11-dihydroxy-9,11-secocholest-5-en-9-one|3beta-3,11-Dihydroxy-9,11-secocholest-5-en-9-one

C27H46O3 (418.3447)


   

2-O-[(3R,9R)-3,9-dihydroxyeicosanoyl]glycerol

2-O-[(3R,9R)-3,9-dihydroxyeicosanoyl]glycerol

C23H46O6 (418.3294)


   

seco-plakortolide K

seco-plakortolide K

C26H42O4 (418.3083)


A butan-4-olide that is dihydrofuran-2(3H)-one substituted by a hydroxy group at position 4, a 2-hydroxy-2-methyl-14-phenyltetradecyl group at position 5 and a methyl group at position 5 (the 4R,5R stereoisomer). It is isolated from the Australian marine sponge Plakinastrella clathrata.

   

22, 23-Dihydro-(3beta, 5alpha, 6beta, 22E)-Cholesta-7, 22-diene-3, 5, 6-triol, 9CI

22, 23-Dihydro-(3beta, 5alpha, 6beta, 22E)-Cholesta-7, 22-diene-3, 5, 6-triol, 9CI

C27H46O3 (418.3447)


   

12beta,16beta-dihydroxy-24-methyl-24-oxoscalaran-25-al

12beta,16beta-dihydroxy-24-methyl-24-oxoscalaran-25-al

C26H42O4 (418.3083)


   

cholest-5-ene-3beta,4beta,22(R)-triol

cholest-5-ene-3beta,4beta,22(R)-triol

C27H46O3 (418.3447)


   

Di-Ac-2-Methyl-5-pentadecyl-1,3-benzenediol

Di-Ac-2-Methyl-5-pentadecyl-1,3-benzenediol

C26H42O4 (418.3083)


   

Digalogenin

Digalogenin

C26H42O4 (418.3083)


   

(1alpha, 3beta, 11alpha)-Cholest-5-ene-1, 3, 11-triol

(1alpha, 3beta, 11alpha)-Cholest-5-ene-1, 3, 11-triol

C27H46O3 (418.3447)


   

(3S,5E,7E,10S)-9,10-Secocholesta-5,7-diene-3,24,25-triol

(3S,5E,7E,10S)-9,10-Secocholesta-5,7-diene-3,24,25-triol

C27H46O3 (418.3447)


   

3,7,11,15-tetramethyl-n-octadec-13-ene-3,4,6,7,8,11-hexol-12-one

3,7,11,15-tetramethyl-n-octadec-13-ene-3,4,6,7,8,11-hexol-12-one

C22H42O7 (418.293)


   

3beta-hydroxy-5beta-hydroxy-B-norcholestane-6beta-carboxaldehyde

3beta-hydroxy-5beta-hydroxy-B-norcholestane-6beta-carboxaldehyde

C27H46O3 (418.3447)


   

3,6,9,12,15,19,22,25,28-hentriacontanonaene

3,6,9,12,15,19,22,25,28-hentriacontanonaene

C31H46 (418.3599)


   

9-Hydroxy-9-apo-epsilon-caroten-3-one

9-Hydroxy-9-apo-epsilon-caroten-3-one

C29H38O2 (418.2872)


   

Guggulsterol-II

Guggulsterol-II

C27H46O3 (418.3447)


   
   

Saxosterol

cholest-5-en-3beta,16beta,22R-triol

C27H46O3 (418.3447)


   

(5alpha,12beta,16beta,17alpha,17abeta)-17a,20-lactone-12,16,20-trihydroxy-4,4,8-trimethyl-D(17a)-homopregnane-17a-carboxylic acid|12,16-dihydroxy-24-methylscalaran-25,24-olide

(5alpha,12beta,16beta,17alpha,17abeta)-17a,20-lactone-12,16,20-trihydroxy-4,4,8-trimethyl-D(17a)-homopregnane-17a-carboxylic acid|12,16-dihydroxy-24-methylscalaran-25,24-olide

C26H42O4 (418.3083)


   

3beta-amino-20alphaF-dimethylamino-4beta-hydroxymethyl-4alpha,14-dimethyl-(5alpha)-9beta,19-cyclo-pregnan-16alpha-ol|Dihydro-cyclo-microphyllin F|Dihydrocyclomicrophyllin-F|Dihydromicrophyllin-F

3beta-amino-20alphaF-dimethylamino-4beta-hydroxymethyl-4alpha,14-dimethyl-(5alpha)-9beta,19-cyclo-pregnan-16alpha-ol|Dihydro-cyclo-microphyllin F|Dihydrocyclomicrophyllin-F|Dihydromicrophyllin-F

C26H46N2O2 (418.3559)


   

isoplexigenin B

isoplexigenin B

C26H42O4 (418.3083)


   

(10R)-3c,5t,8t-Trihydroxy-10r,13c-dimethyl-17c-((R)-1,5-dimethyl-hexyl)-(9tH,14tH)-Delta6-tetradecahydro-1H-cyclopenta[a]phenanthren|3beta,5,8-Trihydroxy-10,13-dimethyl-17beta-((R)-1,5-dimethyl-hexyl)-5alpha,8alpha-gonen-(6)|3beta,5alpha,8alpha-Trihydroxycholest-6-en|5alpha,8alpha-Cholesten-(6)-triol-(3beta,5,8)|5alpha,8alpha-cholestene-(6)-triol-(3beta,5,8)|5alpha,8alpha-epidioxy-cholest-6-ene-3-ol

(10R)-3c,5t,8t-Trihydroxy-10r,13c-dimethyl-17c-((R)-1,5-dimethyl-hexyl)-(9tH,14tH)-Delta6-tetradecahydro-1H-cyclopenta[a]phenanthren|3beta,5,8-Trihydroxy-10,13-dimethyl-17beta-((R)-1,5-dimethyl-hexyl)-5alpha,8alpha-gonen-(6)|3beta,5alpha,8alpha-Trihydroxycholest-6-en|5alpha,8alpha-Cholesten-(6)-triol-(3beta,5,8)|5alpha,8alpha-cholestene-(6)-triol-(3beta,5,8)|5alpha,8alpha-epidioxy-cholest-6-ene-3-ol

C27H46O3 (418.3447)


   

(3beta, 5alpha, 6alpha, 23?鈥?-Cholest-9(11)-ene-3, 6, 23-triol

(3beta, 5alpha, 6alpha, 23?鈥?-Cholest-9(11)-ene-3, 6, 23-triol

C27H46O3 (418.3447)


   

(3S,5E,7E,10S)-9,10-Secocholesta-5,7-diene-3,23,25-triol

(3S,5E,7E,10S)-9,10-Secocholesta-5,7-diene-3,23,25-triol

C27H46O3 (418.3447)


   

3,5-Dihydroxycholestan-6-one

3,5-Dihydroxycholestan-6-one

C27H46O3 (418.3447)


   

SCHEMBL11044088

SCHEMBL11044088

C26H42O4 (418.3083)


   

2,5-dihydroxy-3-methyl-6-nonadec-14-enylcyclohexa-2,5-diene-1,4-dione

2,5-dihydroxy-3-methyl-6-nonadec-14-enylcyclohexa-2,5-diene-1,4-dione

C26H42O4 (418.3083)


   

3,7,11,15-tetramethyl-n-hexadecan-3alpha-ol-1-yl benzoate|orizaditerpenyl benzoate

3,7,11,15-tetramethyl-n-hexadecan-3alpha-ol-1-yl benzoate|orizaditerpenyl benzoate

C27H46O3 (418.3447)


   

2-(4-hydroxyphenyl)ethyl nonadecanoate

2-(4-hydroxyphenyl)ethyl nonadecanoate

C27H46O3 (418.3447)


   

7alpha-p-isopropyl-benzyl-ferruginol

7alpha-p-isopropyl-benzyl-ferruginol

C30H42O (418.3235)


   

SCHEMBL15976038

SCHEMBL15976038

C26H42O4 (418.3083)


   

3.alpha.,7.beta.-Dihydroxy-5.beta.,6.beta.-epoxycholestane

3.alpha.,7.beta.-Dihydroxy-5.beta.,6.beta.-epoxycholestane

C27H46O3 (418.3447)


   

Pallasone C

Pallasone C

C26H42O4 (418.3083)


   

(3beta, 7beta)-Cholest-5-ene-3, 7, 19-triol|5-cholesten-3beta,7beta,19-triol|cholest-5-en-3beta,7beta,19-triol|cholest-5-ene-3,7,19-triol

(3beta, 7beta)-Cholest-5-ene-3, 7, 19-triol|5-cholesten-3beta,7beta,19-triol|cholest-5-en-3beta,7beta,19-triol|cholest-5-ene-3,7,19-triol

C27H46O3 (418.3447)


   

4-hydroxymethyl-7-(2,2,6-trimethylcyclohexyl)-heptanyl 2,6,6-trimethylcyclohexa-1,3-diene-1-carboxylate

4-hydroxymethyl-7-(2,2,6-trimethylcyclohexyl)-heptanyl 2,6,6-trimethylcyclohexa-1,3-diene-1-carboxylate

C27H46O3 (418.3447)


   

cholest-7-ene-3,6,9-triol

cholest-7-ene-3,6,9-triol

C27H46O3 (418.3447)


   

5,6-seco-5-oxo-cholestan-6-oic acid|5-oxo-5,6-seco-cholestan-6-oic acid|5-Oxo-5,6-seco-cholestan-6-saeure|5-Oxo-5,6-seco-cholestansaeure-(6)|5-Oxo-5.6-seco-cholestansaeure-(6)

5,6-seco-5-oxo-cholestan-6-oic acid|5-oxo-5,6-seco-cholestan-6-oic acid|5-Oxo-5,6-seco-cholestan-6-saeure|5-Oxo-5,6-seco-cholestansaeure-(6)|5-Oxo-5.6-seco-cholestansaeure-(6)

C27H46O3 (418.3447)


   

(5Z,8Z,10E,12R,14Z)-methyl 12-(3-methyl-1-oxobutoxy)-5,8,10,14-eicosatetraenoate|dichotellate B

(5Z,8Z,10E,12R,14Z)-methyl 12-(3-methyl-1-oxobutoxy)-5,8,10,14-eicosatetraenoate|dichotellate B

C26H42O4 (418.3083)


   

hexadecanyl 2-hydroxy-4-methoxycinnamate

hexadecanyl 2-hydroxy-4-methoxycinnamate

C26H42O4 (418.3083)


   

(22E)-1beta,3beta,5alpha-trihydroxy-24-norcholest-22-en-6-one

(22E)-1beta,3beta,5alpha-trihydroxy-24-norcholest-22-en-6-one

C26H42O4 (418.3083)


   

SCHEMBL10326064

SCHEMBL10326064

C22H42O7 (418.293)


   

astropectenol A

astropectenol A

C27H46O3 (418.3447)


   

3beta-O-acetyl-12beta-hydroxy-23,24,25,26,27-hexanordammarane-20-one

3beta-O-acetyl-12beta-hydroxy-23,24,25,26,27-hexanordammarane-20-one

C26H42O4 (418.3083)


   

cholest-24-ene-3beta,5alpha,6beta-triol|muriflasteroid C

cholest-24-ene-3beta,5alpha,6beta-triol|muriflasteroid C

C27H46O3 (418.3447)


   

(22E)-cholest-22-ene-3beta,5alpha,6beta-triol

(22E)-cholest-22-ene-3beta,5alpha,6beta-triol

C27H46O3 (418.3447)


   

24-nor-3beta,6alpha,11-trihydroxy-9,11-seco-5alpha-cholest-7,22(E)-dien-9-one

24-nor-3beta,6alpha,11-trihydroxy-9,11-seco-5alpha-cholest-7,22(E)-dien-9-one

C26H42O4 (418.3083)


   

1beta,3beta-dihydroxycholestan-6-one

1beta,3beta-dihydroxycholestan-6-one

C27H46O3 (418.3447)


   

cholest-5-en-1alpha,3beta,4alpha-triol|easitoerol 3

cholest-5-en-1alpha,3beta,4alpha-triol|easitoerol 3

C27H46O3 (418.3447)


   

aculeatin B

aculeatin B

C26H42O4 (418.3083)


   

Guggulsterol II

Guggulsterol II

C27H46O3 (418.3447)


   

5alpha-cholest-14-ene-3beta,6alpha,24xi-triol

5alpha-cholest-14-ene-3beta,6alpha,24xi-triol

C27H46O3 (418.3447)


   

bis(2-ethylheptyl) benzene-1,2-dicarboxylate

bis(2-ethylheptyl) benzene-1,2-dicarboxylate

C26H42O4 (418.3083)


   

(16S,20S)-16,20-dihydroxycholestan-3-one

(16S,20S)-16,20-dihydroxycholestan-3-one

C27H46O3 (418.3447)


   

2-O-[(3R,6S)-3,6-dihydroxyeicosanoyl]glycerol

2-O-[(3R,6S)-3,6-dihydroxyeicosanoyl]glycerol

C23H46O6 (418.3294)


   

plakinic acid K

plakinic acid K

C26H42O4 (418.3083)


   

plakinic acid M

plakinic acid M

C26H42O4 (418.3083)


   

2-O-[(3R,8R)-3,8-dihydroxyeicosanoyl]glycerol

2-O-[(3R,8R)-3,8-dihydroxyeicosanoyl]glycerol

C23H46O6 (418.3294)


   

2-O-[(3R,7R)-3,7-dihydroxyeicosanoyl]glycerol

2-O-[(3R,7R)-3,7-dihydroxyeicosanoyl]glycerol

C23H46O6 (418.3294)


   

3beta-hydroxy-5-oxo-5,6-secocholestan-6-al

3beta-hydroxy-5-oxo-5,6-secocholestan-6-al

C27H46O3 (418.3447)


   

Axinellamine B

Axinellamine B

C29H42N2 (418.3348)


   

ent-3beta-angeloyloxy-16beta-methoxy-17-hydroxykaurane

ent-3beta-angeloyloxy-16beta-methoxy-17-hydroxykaurane

C26H42O4 (418.3083)


   

5alpha-Cholestan-3beta,6alpha-diol-23-on|Tetrahydromarthasteron

5alpha-Cholestan-3beta,6alpha-diol-23-on|Tetrahydromarthasteron

C27H46O3 (418.3447)


   

decyl octyl phthalate

OCTYL DECYL PHTHALATE

C26H42O4 (418.3083)


   

19-(1,3-Benzodioxole-5-yl)nonadecanoic acid

19-(1,3-Benzodioxole-5-yl)nonadecanoic acid

C26H42O4 (418.3083)


   

1-O-Palmitoyl-D-fructopyranose|hexadecanoic 1-O-beta-D-fructoside|hexadecanoic fructoside

1-O-Palmitoyl-D-fructopyranose|hexadecanoic 1-O-beta-D-fructoside|hexadecanoic fructoside

C22H42O7 (418.293)


   

(3S,5Z,10xi)-3,10-Dihydroxy-9,10-secocholest-5-en-7-one

(3S,5Z,10xi)-3,10-Dihydroxy-9,10-secocholest-5-en-7-one

C27H46O3 (418.3447)


   

5-(2-Oxohenicosyl)resorcinol

5-(2-Oxohenicosyl)resorcinol

C27H46O3 (418.3447)


   

hexadecyl (E)-3-(4-hydroxy-3-methoxyphenyl)prop-2-enoate

NCGC00386025-01!hexadecyl (E)-3-(4-hydroxy-3-methoxyphenyl)prop-2-enoate

C26H42O4 (418.3083)


   

hexadecyl (E)-3-(4-hydroxy-3-methoxyphenyl)prop-2-enoate [IIN-based: Match]

NCGC00386025-01!hexadecyl (E)-3-(4-hydroxy-3-methoxyphenyl)prop-2-enoate [IIN-based: Match]

C26H42O4 (418.3083)


   

Cholesterol-5beta-hydroperoxide

3beta-hydroxy-5beta-cholest-6-ene-5-hydroperoxide

C27H46O3 (418.3447)


   

cholest-5-en-3β,7α,12α-triol

cholest-5-en-3β,7α,12α-triol

C27H46O3 (418.3447)


   

Dormatinol

cholest-5-en-3beta,22S,26S-triol

C27H46O3 (418.3447)


   

1,25-Dihydroxycholesterol

cholest-5-ene-1alpha,3beta,25-triol

C27H46O3 (418.3447)


   

3,5-dihydroxy-B-norcholestane-6-carboxaldehyde

3beta,5beta-dihydroxy-b-norcholestan-6beta-carboxaldehyde

C27H46O3 (418.3447)


   

6-Oxo-3,5-diol

cholestan-6-oxo-3β,5α-diol

C27H46O3 (418.3447)


   

3beta,5-oxo-5,6-secocholestan-6-al

3β,5-oxo-5,6-secocholestan-6-al

C27H46O3 (418.3447)


   

24S,25-dihydroxycholesterol

cholest-5-en-3beta,24S,25-triol

C27H46O3 (418.3447)


   

24S,27-dihydroxycholesterol

cholest-5-en-3beta,24S,26-triol

C27H46O3 (418.3447)


   

7α,25-dihydroxycholesterol

cholest-5-en-3beta,7alpha,25-triol

C27H46O3 (418.3447)


   

25,27-dihydroxycholesterol

cholest-5-en-3beta,25,26-triol

C27H46O3 (418.3447)


   

6,24S-dihydroxycholesterol

cholest-5-en-3beta,6,24S-triol

C27H46O3 (418.3447)


   

(5Z,7E)-(1R)-9,10-seco-3-thia-5,7,10(19)-cholestatriene-1,25-diol

1α,25-dihydroxy-3-deoxy-3-thiavitamin D3 / 1α,25-dihydroxy-3-deoxy-3-thiacholecalciferol

C26H42O2S (418.2905)


   

(5Z,7E)-(1S)-9,10-seco-3-thia-5,7,10(19)-cholestatriene-1,25-diol

1β,25-dihydroxy-3-deoxy-3-thiavitamin D3 / 1β,25-dihydroxy-3-deoxy-3-thiacholecalciferol

C26H42O2S (418.2905)


   

(5Z)-1,25-dihydroxy-3-thiavitamin D3 / (5Z)-1,25-dihydroxy-3-thiacholecalciferol

(5Z)-1,25-dihydroxy-3-thiavitamin D3 / (5Z)-1,25-dihydroxy-3-thiacholecalciferol

C26H42O2S (418.2905)


   

(24R)-1α,24-dihydroxy-22-oxavitamin D3 / (24R)-1α,24-dihydroxy-22-oxacholecalciferol

(24R)-1α,24-dihydroxy-22-oxavitamin D3 / (24R)-1α,24-dihydroxy-22-oxacholecalciferol

C26H42O4 (418.3083)


   

(5Z,7E)-(1S,3R,20R,24R)-22-oxa-9,10-seco-5,7,10(19)-cholestatriene-1,3,24-triol

(24R)-1α,24-dihydroxy-22-oxa-20-epivitamin D3 / (24R)-1α,24-dihydroxy-22-oxa-20-epicholecalciferol

C26H42O4 (418.3083)


   

(24S)-1α,24-dihydroxy-22-oxavitamin D3 / (24S)-1α,24-dihydroxy-22-oxacholecalciferol

(24S)-1α,24-dihydroxy-22-oxavitamin D3 / (24S)-1α,24-dihydroxy-22-oxacholecalciferol

C26H42O4 (418.3083)


   

(5Z,7E)-(1S,3R,20R,24S)-22-oxa-9,10-seco-5,7,10(19)-cholestatriene-1,3,24-triol

(24S)-1α,24-dihydroxy-22-oxa-20-epivitamin D3 / (24S)-1α,24-dihydroxy-22-oxa-20-epicholecalciferol

C26H42O4 (418.3083)


   

1α,25-dihydroxy-22-oxavitamin D3 / 1α,25-dihydroxy-22-oxacholecalciferol

1α,25-dihydroxy-22-oxavitamin D3 / 1α,25-dihydroxy-22-oxacholecalciferol

C26H42O4 (418.3083)


   

1α,25-dihydroxy-22-oxa-20-epivitamin D3 / 1α,25-dihydroxy-22-oxa-20-epicholecalciferol

1α,25-dihydroxy-22-oxa-20-epivitamin D3 / 1α,25-dihydroxy-22-oxa-20-epicholecalciferol

C26H42O4 (418.3083)


   

1β,25-dihydroxy-22-oxavitamin D3 / 1β,25-dihydroxy-22-oxacholecalciferol

1β,25-dihydroxy-22-oxavitamin D3 / 1β,25-dihydroxy-22-oxacholecalciferol

C26H42O4 (418.3083)


   

1α,25-dihydroxy-23-oxavitamin D3 / 1α,25-dihydroxy-23-oxacholecalciferol

1α,25-dihydroxy-23-oxavitamin D3 / 1α,25-dihydroxy-23-oxacholecalciferol

C26H42O4 (418.3083)


   

(5Z,7E)-(1S,3R,20S)-24-nor-9,10-seco-5,7,10(19)-cholestatriene-1,3,20,25-tetrol

(20S)-1α,20,25-trihydroxy-24-norvitamin D3/(20S)-1α,20,25-trihydroxy-24-norcholecalciferol

C26H42O4 (418.3083)


   

(5Z,7E,10Z)-(1S,3R)-19-fluoro-9,10-seco-5,7,10(19)-cholestatriene-1,3-diol

(5Z,10Z)-19-fluoro-1α-hydroxyvitamin-D3 / (5Z,10Z)-19-fluoro-1α-hydroxycholecalciferol

C27H43FO2 (418.3247)


   

(5Z,7E,10E)-(1S,3R)-19-fluoro-9,10-seco-5,7,10(19)-cholestatriene-1,3-diol

(5Z,10E)-19-fluoro-1α-hydroxyvitamin-D3 / (5Z,10E)-19-fluoro-1α-hydroxycholecalciferol

C27H43FO2 (418.3247)


   

(5E,7E,10Z)-(1S,3R)-19-fluoro-9,10-seco-5,7,10(19)-cholestatriene-1,3-diol

(5E,10Z)-19-fluoro-1α-hydroxyvitamin-D3 / (5E,10Z)-19-fluoro-1α-hydroxycholecalciferol

C27H43FO2 (418.3247)


   

(5E,7E,10E)-(1S,3R)-19-fluoro-9,10-seco-5,7,10(19)-cholestatriene-1,3-diol

(5E,10E)-19-fluoro-1α-hydroxyvitamin-D3 / (5E,10E)-19-fluoro-1α-hydroxycholecalciferol

C27H43FO2 (418.3247)


   

25-fluoro-1α-hydroxyvitamin D3 / 25-fluoro-1α-hydroxycholecalciferol

25-fluoro-1α-hydroxyvitamin D3 / 25-fluoro-1α-hydroxycholecalciferol

C27H43FO2 (418.3247)


   

(24R)-25-fluoro-24-hydroxyvitamin D3 / (24R)-25-fluoro-24-hydroxycholecalciferol

(24R)-25-fluoro-24-hydroxyvitamin D3 / (24R)-25-fluoro-24-hydroxycholecalciferol

C27H43FO2 (418.3247)


   

1α-fluoro-25-hydrovitamin D3 / 1α-fluoro-25-hydrocholecalciferol

1α-fluoro-25-hydrovitamin D3 / 1α-fluoro-25-hydrocholecalciferol

C27H43FO2 (418.3247)


   

24-fluoro-25-hydroxyvitamin D3 / 24-fluoro-25-hydroxycholecalciferol

(5Z,7E)-(3S)-24-fluoro-9,10-seco-5,7,10(19)-cholestatriene-3,25-diol

C27H43FO2 (418.3247)


   

1-methyl-1,25-dihydroxy-4-nor-2,3-secovitamin D3 / 1-methyl-1,25-dihydroxy-4-nor-2,3-secocholecalciferol

1-methyl-1,25-dihydroxy-4-nor-2,3-secovitamin D3 / 1-methyl-1,25-dihydroxy-4-nor-2,3-secocholecalciferol

C27H46O3 (418.3447)


   

(7E)-(1R,2S,3R)-2-methyl-19-nor-9,10-seco-5,7-cholestadiene-1,3,25-triol

1α,25-dihydroxy-2α-methyl-19-norvitamin D3 / 1α,25-dihydroxy-2α-methyl-19-norcholecalciferol

C27H46O3 (418.3447)


   

(7E)-(1R,2R,3R)-2-methyl-19-nor-9,10-seco-5,7-cholestadiene-1,3,25-triol

1α,25-dihydroxy-2β-methyl-19-norvitamin D3 / 1α,25-dihydroxy-2β-methyl-19-norcholecalciferol

C27H46O3 (418.3447)


   

(7E)-(1R,2S,3R,20S)-2-methyl-19-nor-9,10-seco-5,7-cholestadiene-1,3,25-triol

1α,25-dihydroxy-2α-methyl-19-nor-20-epivitamin D3 / 1α,25-dihydroxy-2α-methyl-19-nor-20-epicholecalciferol

C27H46O3 (418.3447)


   

(7E)-(1R,2R,3R,20S)-2-methyl-19-nor-9,10-seco-5,7-cholestadiene-1,3,25-triol

1α,25-dihydroxy-2β-methyl-19-nor-20-epivitamin D3 / 1α,25-dihydroxy-2β-methyl-19-nor-20-epicholecalciferol

C27H46O3 (418.3447)


   

1-Fluoro-25-hydroxy-16-ene-23-yne-26,27-hexadeuterovitamin-D3

(5Z,7E,16Z)-(1S,3R)-1-fluoro-13-yne-26,26,26,27,27,27-hexadeutero-9,10-seco-5,7,10(19),16-cholestatetraen-3,25-diol

C27H31D6FO2 (418.3154)


   

5β-Cholest-25-ene-3α,7α,12α-triol

5β-Cholest-25-ene-3α,7α,12α-triol

C27H46O3 (418.3447)


   

3β-Hydroxy-5β-cholestan-26-oic acid

3β-Hydroxy-5β-cholestan-26-oic acid

C27H46O3 (418.3447)


   

3α-Hydroxy-5β-cholestan-26-oic acid

3α-Hydroxy-5β-cholestan-26-oic acid

C27H46O3 (418.3447)


   

5α-Cholest-25-ene-3α,7α,12α-triol

5α-Cholest-25-ene-3α,7α,12α-triol

C27H46O3 (418.3447)


   

7α,25-Dihydroxy-5β-cholestan-3-one

7α,25-Dihydroxy-5β-cholestan-3-one

C27H46O3 (418.3447)


   

3α,12α-Dihydroxy-5β-cholestan-7-one

3α,12α-Dihydroxy-5β-cholestan-7-one

C27H46O3 (418.3447)


   

Cholest-4-ene-3α,7α,12α-triol

Cholest-4-ene-3α,7α,12α-triol

C27H46O3 (418.3447)


   

5beta-cholestan-7alpha,26-diol-3-one

7alpha,26-dihydroxy-5beta-cholestan-3-one

C27H46O3 (418.3447)


   

5beta-cholestan-7alpha,24-diol-3-one

7alpha,24alpha-dihydroxy-5beta-cholestan-3-one

C27H46O3 (418.3447)


   

7alpha,24-dihydroxycholesterol

cholest-5-ene-3beta,7alpha,24-triol

C27H46O3 (418.3447)


   

(24R)-7alpha,24-dihydroxycholesterol

(24R)-cholest-5-ene-3beta,7alpha,24-triol

C27H46O3 (418.3447)


   

Pglcua

Hexadecylbeta-delta-glucopyranosiduronic acid

C22H42O7 (418.293)


   

Dichotellate A

Methyl 12R-(3-methylbutanoyloxy)-5Z,8E,10E,14Z-eicosatetraenoate

C26H42O4 (418.3083)


   

Dichotellate B

Methyl 12R-(3-methylbutanoyloxy)-5Z,8Z,10E,14Z-eicosatetraenoate

C26H42O4 (418.3083)


   

C31:9 hydrocarbon

3Z,6Z,9Z,12Z,15Z,19Z,22Z,25Z,28Z-Hentriacontanonaene

C31H46 (418.3599)


   

5beta-Cholest-25-ene-3alpha,7alpha,12alpha-triol

5beta-Cholest-25-ene-3alpha,7alpha,12alpha-triol

C27H46O3 (418.3447)


   

3beta-Hydroxy-5beta-cholestan-26-oic acid

3beta-Hydroxy-5beta-cholestan-26-oic acid

C27H46O3 (418.3447)


   

3alpha-Hydroxy-5beta-cholestan-26-oic acid

3alpha-Hydroxy-5beta-cholestan-26-oic acid

C27H46O3 (418.3447)


   

5alpha-Cholest-25-ene-3alpha,7alpha,12alpha-triol

5alpha-Cholest-25-ene-3alpha,7alpha,12alpha-triol

C27H46O3 (418.3447)


   

7alpha,25-Dihydroxy-5beta-cholestan-3-one

7alpha,25-Dihydroxy-5beta-cholestan-3-one

C27H46O3 (418.3447)


   

3alpha,12alpha-Dihydroxy-5beta-cholestan-7-one

3alpha,12alpha-Dihydroxy-5beta-cholestan-7-one

C27H46O3 (418.3447)


   

Cholest-4-ene-3alpha,7alpha,12alpha-triol

Cholest-4-ene-3alpha,7alpha,12alpha-triol

C27H46O3 (418.3447)


   

cholest-5-en-3beta,7alpha,12alpha-triol

cholest-5-en-3beta,7alpha,12alpha-triol

C27H46O3 (418.3447)


   

7beta,26-dihydroxycholesterol

(25R)-cholest-5-en-3beta,7beta,27-triol

C27H46O3 (418.3447)


   

16alpha,26-dihydroxycholesterol

(25R)-cholest-5-en-3beta,16alpha,27-triol

C27H46O3 (418.3447)


   

b-Citraurinene

3,5,5-trimethyl-4-[(1E,3Z,5E,7E,9E,11Z,13E)-3,7,12,16-tetramethylheptadeca-1,3,5,7,9,11,13,15-octaen-1-yl]cyclohex-3-en-1-ol

C30H42O (418.3235)


   

Hexadecyl ferulate

hexadecyl (2Z)-3-(4-hydroxy-3-methoxyphenyl)prop-2-enoate

C26H42O4 (418.3083)


   

WE 26:5;O2

Cis-Hydroxytyrosol Oleate;Oleic acid 3,4-dihydroxyphenethyl ester

C26H42O4 (418.3083)


   

3Z,6Z,9Z,12Z,15Z,19Z,22Z,25Z,28Z-Hentriacontanonaene

3Z,6Z,9Z,12Z,15Z,19Z,22Z,25Z,28Z-Hentriacontanonaene

C31H46 (418.3599)


   

bhas#28

3R-hydroxy-15R-(3R,5R-dihydroxy-6S-methyl-(2H)-tetrahydropyran-2-yloxy)-hexadecanoic acid

C22H42O7 (418.293)


An (omega-1)-hydroxy fatty acid ascaroside that is ascr#28 in which the pro-R hydrogen that is beta to the carboxy group is replaced by a hydroxy group. It is a metabolite of the nematode Caenorhabditis elegans.

   

bhos#28

3R-hydroxy-16-(3R,5R-dihydroxy-6S-methyl-(2H)-tetrahydropyran-2-yloxy)-hexadecanoic acid

C22H42O7 (418.293)


An omega-hydroxy fatty acid ascaroside that is (3R)-3,16-dihydroxyhexadecanoic acid (oscr#28) in which the hydroxy group at position 16 has been converted to the corresponding ascaroside. It is a metabolite of the nematode Caenorhabditis elegans.

   

MG O-23:6;O

1-O-(2R-methoxy-4Z,7Z,10Z,13Z,16Z,19Z-docosahexaenyl)-sn-glycerol

C26H42O4 (418.3083)


   

ST 27:1;O3

(20R,22R)-20,22-Dihydroxycholesterol;(22R)-20alpha,22-Dihydroxycholesterol

C27H46O3 (418.3447)


7α, 25-dihydroxycholesterol (7α,25-OHC) is a potent and selective agonist and endogenous ligand of the orphan GPCR receptor EBI2 (GPR183). 7α, 25-dihydroxycholesterol is highly potent at activating EBI2 (EC50=140 pM; Kd=450 pM). 7α, 25-dihydroxycholesterol can serve as a chemokine directing migration of B cells, T cells and dendritic cells[1][2].

   

Atheronal-B

3beta,5beta-dihydroxy-b-norcholestan-6beta-carboxaldehyde

C27H46O3 (418.3447)


   

Atheronal-A

3beta,5-oxo-5,6-secocholestan-6-al

C27H46O3 (418.3447)


   

ST 26:2;O4

24-nor-3beta,6alpha,20S-trihydroxy-5alpha-cholest-9(11)-en-23-one

C26H42O4 (418.3083)


   

Calibagenin

cholest-5-en-3beta,16beta,22S-triol

C27H46O3 (418.3447)


   

1alpha,25-dihydroxy-3-deoxy-3-thiavitamin D3

(5E,7E)-(1R)-9,10-seco-3-thia-5,7,10(19)-cholestatriene-1,25-diol

C26H42O2S (418.2905)


   

1beta,25-dihydroxy-3-deoxy-3-thiavitamin D3

(5Z,7E)-(1S)-9,10-seco-3-thia-5,7,10(19)-cholestatriene-1,25-diol

C26H42O2S (418.2905)


   

(5Z)-1,25-dihydroxy-3-thiavitamin D3

(5Z,7E)-(1R)-9,10-seco-3-thia-5,7,10(19)-cholestatriene-1,25-diol

C26H42O2S (418.2905)


   

(24R)-1alpha,24-dihydroxy-22-oxavitamin D3 / (24R)-1alpha,24-dihydroxy-22-oxacholecalciferol

(24R)-1alpha,24-dihydroxy-22-oxavitamin D3 / (24R)-1alpha,24-dihydroxy-22-oxacholecalciferol

C26H42O4 (418.3083)


   

(24R)-1alpha,24-dihydroxy-22-oxa-20-epivitamin D3

(5Z,7E)-(1S,3R,20R,24R)-22-oxa-9,10-seco-5,7,10(19)-cholestatriene-1,3,24-triol

C26H42O4 (418.3083)


   

(24S)-1alpha,24-dihydroxy-22-oxavitamin D3 / (24S)-1alpha,24-dihydroxy-22-oxacholecalciferol

(24S)-1alpha,24-dihydroxy-22-oxavitamin D3 / (24S)-1alpha,24-dihydroxy-22-oxacholecalciferol

C26H42O4 (418.3083)


   

(24S)-1alpha,24-dihydroxy-22-oxa-20-epivitamin D3

(5Z,7E)-(1S,3R,20R,24S)-22-oxa-9,10-seco-5,7,10(19)-cholestatriene-1,3,24-triol

C26H42O4 (418.3083)


   

1alpha,25-dihydroxy-22-oxavitamin D3 / 1alpha,25-dihydroxy-22-oxacholecalciferol

1alpha,25-dihydroxy-22-oxavitamin D3 / 1alpha,25-dihydroxy-22-oxacholecalciferol

C26H42O4 (418.3083)


   

1alpha,25-dihydroxy-22-oxa-20-epivitamin D3

(5Z,7E)-(1S,3R,20R)-22-oxa-9,10-seco-5,7,10(19)-cholestatriene-1,3,25-triol

C26H42O4 (418.3083)


   

1beta,25-dihydroxy-22-oxavitamin D3 / 1beta,25-dihydroxy-22-oxacholecalciferol

1beta,25-dihydroxy-22-oxavitamin D3 / 1beta,25-dihydroxy-22-oxacholecalciferol

C26H42O4 (418.3083)


   

1alpha,25-dihydroxy-23-oxavitamin D3 / 1alpha,25-dihydroxy-23-oxacholecalciferol

1alpha,25-dihydroxy-23-oxavitamin D3 / 1alpha,25-dihydroxy-23-oxacholecalciferol

C26H42O4 (418.3083)


   

(20S)-1alpha,20,25-trihydroxy-24-norvitamin D3

(5Z,7E)-(1S,3R,20S)-24-nor-9,10-seco-5,7,10(19)-cholestatriene-1,3,20,25-tetrol

C26H42O4 (418.3083)


   

(5Z,10Z)-19-fluoro-1alpha-hydroxyvitamin-D3 / (5Z,10Z)-19-fluoro-1alpha-hydroxycholecalciferol

(5Z,10Z)-19-fluoro-1alpha-hydroxyvitamin-D3 / (5Z,10Z)-19-fluoro-1alpha-hydroxycholecalciferol

C27H43FO2 (418.3247)


   

(5Z,10E)-19-fluoro-1alpha-hydroxyvitamin-D3 / (5Z,10E)-19-fluoro-1alpha-hydroxycholecalciferol

(5Z,10E)-19-fluoro-1alpha-hydroxyvitamin-D3 / (5Z,10E)-19-fluoro-1alpha-hydroxycholecalciferol

C27H43FO2 (418.3247)


   

(5E,10Z)-19-fluoro-1alpha-hydroxyvitamin-D3 / (5E,10Z)-19-fluoro-1alpha-hydroxycholecalciferol

(5E,10Z)-19-fluoro-1alpha-hydroxyvitamin-D3 / (5E,10Z)-19-fluoro-1alpha-hydroxycholecalciferol

C27H43O2F (418.3247)


   

(5E,10E)-19-fluoro-1alpha-hydroxyvitamin-D3 / (5E,10E)-19-fluoro-1alpha-hydroxycholecalciferol

(5E,10E)-19-fluoro-1alpha-hydroxyvitamin-D3 / (5E,10E)-19-fluoro-1alpha-hydroxycholecalciferol

C27H43FO2 (418.3247)


   

25-fluoro-1alpha-hydroxyvitamin D3

(5Z,7E)-(1S,3R)-25-fluoro-9,10-seco-5,7,10(19)-cholestatriene-1,3-diol

C27H43O2F (418.3247)


   

1alpha-fluoro-25-hydrovitamin D3

(5Z,7E)-(1S,3R)-3-fluoro-9,10-seco-5,7,10(19)-cholestatriene-3,25-diol

C27H43O2F (418.3247)


   

24-fluoro-25-hydroxyvitamin D3

(5Z,7E)-(3S)-24-fluoro-9,10-seco-5,7,10(19)-cholestatriene-3,25-diol

C27H43O2F (418.3247)


   

1alpha,25-dihydroxy-2alpha-methyl-19-norvitamin D3

(7E)-(1R,2S,3R)-2-methyl-19-nor-9,10-seco-5,7-cholestadiene-1,3,25-triol

C27H46O3 (418.3447)


   

1alpha,25-dihydroxy-2beta-methyl-19-norvitamin D3 / 1alpha,25-dihydroxy-2beta-methyl-19-norcholecalciferol

1alpha,25-dihydroxy-2beta-methyl-19-norvitamin D3 / 1alpha,25-dihydroxy-2beta-methyl-19-norcholecalciferol

C27H46O3 (418.3447)


   

1alpha,25-dihydroxy-2alpha-methyl-19-nor-20-epivitamin D3

(7E)-(1R,2S,3R,20S)-2-methyl-19-nor-9,10-seco-5,7-cholestadiene-1,3,25-triol

C27H46O3 (418.3447)


   

1alpha,25-dihydroxy-2beta-methyl-19-nor-20-epivitamin D3

(7E)-(1R,2R,3R,20S)-2-methyl-19-nor-9,10-seco-5,7-cholestadiene-1,3,25-triol

C27H46O3 (418.3447)


   

Hydroxy-3,4-dehydro-apo-8-lycopene

1-Hydroxy-3,4-didehydro-1,2-dihydro-8-apo-psi-carotene

C30H42O (418.3235)


   

9-Hydroxy-9-apo-epsilon,psi-caroten-3-one

9-Hydroxy-9-apo-epsilon,psi-caroten-3-one

C29H38O2 (418.2872)


   

Brachyanone E

Brachyanone E

C26H42O4 (418.3083)


   
   

3,3-(ureylenedimethylene)bis(3,5,5-trimethylcyclohexyl) diisocyanate

3,3-(ureylenedimethylene)bis(3,5,5-trimethylcyclohexyl) diisocyanate

C23H38N4O3 (418.2944)


   

Phosphonic acid,didodecyl ester

Phosphonic acid,didodecyl ester

C24H51O3P (418.3576)


   

2-METHYLACRYLICACID-2-(4-BENZOYL-3-HYDROXYPHENOXY)ETHYLESTER

2-METHYLACRYLICACID-2-(4-BENZOYL-3-HYDROXYPHENOXY)ETHYLESTER

C27H46O3 (418.3447)


   

(S,S)-2,2-METHYLENEBIS(4-PHENYL-2-OXAZOLINE)

(S,S)-2,2-METHYLENEBIS(4-PHENYL-2-OXAZOLINE)

C26H44P2 (418.2918)


   

4-[(3,4-dimethylbenzoyl)amino]-5-(dipentylamino)-5-oxopentanoic acid

4-[(3,4-dimethylbenzoyl)amino]-5-(dipentylamino)-5-oxopentanoic acid

C24H38N2O4 (418.2831)


   

Z-N-ME-DL-ALA-OH DCHA

Z-N-ME-DL-ALA-OH DCHA

C24H38N2O4 (418.2831)


   

N,N-DIHEXYL-2-PHENYLINDOLE-3-ACETAMIDE

N,N-DIHEXYL-2-PHENYLINDOLE-3-ACETAMIDE

C28H38N2O (418.2984)


   

UNII:SN4X38MJ1X

UNII:SN4X38MJ1X

C24H51O3P (418.3576)


   

oxybis(ethane-2,1-diyloxyethane-2,1-diyl) bisheptanoate

oxybis(ethane-2,1-diyloxyethane-2,1-diyl) bisheptanoate

C22H42O7 (418.293)


   

1,2-DIAMINO-4-(TRIFLUOROMETHOXY)BENZENE

1,2-DIAMINO-4-(TRIFLUOROMETHOXY)BENZENE

C26H44P2 (418.2918)


   

Phosphorous acid,trioctyl ester

Phosphorous acid,trioctyl ester

C24H51O3P (418.3576)


   

Phosphorous acid,tris(2-ethylhexyl) ester

Phosphorous acid,tris(2-ethylhexyl) ester

C24H51O3P (418.3576)


   

Calderol

Calcifediol

C27H46O3 (418.3447)


D018977 - Micronutrients > D014815 - Vitamins > D006887 - Hydroxycholecalciferols COVID info from clinicaltrial, clinicaltrials, clinical trial, clinical trials D050071 - Bone Density Conservation Agents Corona-virus Coronavirus SARS-CoV-2 COVID-19 SARS-CoV COVID19 SARS2 SARS

   

valerian root solid extract

valerian root solid extract

C27H46O3 (418.3447)


   

2,3-dihydroxypropyl acetate,octadecanoic acid

2,3-dihydroxypropyl acetate,octadecanoic acid

C23H46O6 (418.3294)


   

bis(3,3,5-trimethylhexyl) benzene-1,2-dicarboxylate

bis(3,3,5-trimethylhexyl) benzene-1,2-dicarboxylate

C26H42O4 (418.3083)


   

3α-hydroxy-6β-ethyl-7-keto-5β-cholanic acid

3α-hydroxy-6β-ethyl-7-keto-5β-cholanic acid

C26H42O4 (418.3083)


   

Maxacalcitol

(5Z)-5-[(2E)-2-[1-[1-(3-hydroxy-3-methylbutoxy)ethyl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]-4-methylidenecyclohexane-1,3-diol

C26H42O4 (418.3083)


D018977 - Micronutrients > D014815 - Vitamins > D004100 - Dihydroxycholecalciferols D018977 - Micronutrients > D014815 - Vitamins > D006887 - Hydroxycholecalciferols D020011 - Protective Agents > D016588 - Anticarcinogenic Agents D000970 - Antineoplastic Agents D003879 - Dermatologic Agents

   

3α-hydroxy-6-ethyl-7-keto-5β-cholan-24-oic acid

3α-hydroxy-6-ethyl-7-keto-5β-cholan-24-oic acid

C26H42O4 (418.3083)


   

ACETOXYLITHOCHOLIC ACID

ACETOXYLITHOCHOLIC ACID

C26H42O4 (418.3083)


   
   
   

(2-Ethylhexyl)phosphonic acid bis(2-ethylhexyl)

(2-Ethylhexyl)phosphonic acid bis(2-ethylhexyl)

C24H51O3P (418.3576)


   

dilauryl phosphite, tech., 85

dilauryl phosphite, tech., 85

C24H51O3P (418.3576)


   

Bis(3,5,5-trimethylhexyl) phthalate

Bis(3,5,5-trimethylhexyl) phthalate

C26H42O4 (418.3083)


   

Valbenazine

Valbenazine

C24H38N2O4 (418.2831)


C78272 - Agent Affecting Nervous System N - Nervous system

   

Bunamidine Hydrochloride

Bunamidine Hydrochloride

C25H39ClN2O (418.2751)


D000890 - Anti-Infective Agents > D000977 - Antiparasitic Agents > D000871 - Anthelmintics C254 - Anti-Infective Agent > C276 - Antiparasitic Agent > C250 - Antihelminthic Agent

   

(3R,15R)-15-[(3,6-dideoxy-alpha-L-arabino-hexopyranosyl)oxy]-3-hydroxyhexadecanoic acid

(3R,15R)-15-[(3,6-dideoxy-alpha-L-arabino-hexopyranosyl)oxy]-3-hydroxyhexadecanoic acid

C22H42O7 (418.293)


   

(3R)-16-[(3,6-dideoxy-alpha-L-arabino-hexopyranosyl)oxy]-3-hydroxyhexadecanoic acid

(3R)-16-[(3,6-dideoxy-alpha-L-arabino-hexopyranosyl)oxy]-3-hydroxyhexadecanoic acid

C22H42O7 (418.293)


   

Cholest-5-ene-3,7,22-triol

Cholest-5-ene-3,7,22-triol

C27H46O3 (418.3447)


   

seco-plakortolide L

seco-plakortolide L

C26H42O4 (418.3083)


A butan-4-olide that is dihydrofuran-2(3H)-one substituted by a hydroxy group at position 4, a 2-hydroxy-2-methyl-14-phenyltetradecyl group at position 5 and a methyl group at position 5 (the 4S,5S stereoisomer). It is isolated from the Australian marine sponge Plakinastrella clathrata.

   

Isodecyl isooctyl phthalate

Isodecyl isooctyl phthalate

C26H42O4 (418.3083)


   

1-{7-Cyclohexyl-6-[4-(4-Methylpiperazin-1-Yl)benzyl]-7h-Pyrrolo[2,3-D]pyrimidin-2-Yl}methanamine

1-{7-Cyclohexyl-6-[4-(4-Methylpiperazin-1-Yl)benzyl]-7h-Pyrrolo[2,3-D]pyrimidin-2-Yl}methanamine

C25H34N6 (418.2845)


   

64190-80-3

(E)-3-(4-hydroxy-3-methoxyphenyl)prop-2-enoic acid hexadecyl ester

C26H42O4 (418.3083)


   

7-hydroperoxy-10,13-dimethyl-17-(6-methylheptan-2-yl)-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-ol

7-hydroperoxy-10,13-dimethyl-17-(6-methylheptan-2-yl)-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-ol

C27H46O3 (418.3447)


D009676 - Noxae > D009153 - Mutagens

   

Yakkasterone

3β,5α-Dihydroxycholestan-6-one

C27H46O3 (418.3447)


   

(24S,25)-dihydroxycholesterol

(24S,25)-dihydroxycholesterol

C27H46O3 (418.3447)


An oxysterol that is cholesterol which is substituted by hydroxy groups at positions 24S and 25.

   

(24S,26)-dihydroxycholesterol

(24S,26)-dihydroxycholesterol

C27H46O3 (418.3447)


An oxysterol that is cholesterol which is substituted by hydroxy groups at positions 24S and 26.

   

(25R)-cholest-5-ene-3beta,7alpha,26-triol

(25R)-cholest-5-ene-3beta,7alpha,26-triol

C27H46O3 (418.3447)


   

4beta,7alpha-dihydroxycholesterol

4beta,7alpha-dihydroxycholesterol

C27H46O3 (418.3447)


An oxysterol that is cholesterol carrying two additional hydroxy groups at the 4beta and 7alpha positions.

   

(20S)-1alpha,20,25-trihydroxy-24-norvitamin D3/(20S)-1alpha,20,25-trihydroxy-24-norcholecalciferol

(20S)-1alpha,20,25-trihydroxy-24-norvitamin D3/(20S)-1alpha,20,25-trihydroxy-24-norcholecalciferol

C26H42O4 (418.3083)


   

4,4-Diaponeurosporenol

4,4-Diaponeurosporenol

C30H42O (418.3235)


   

22(r),26-Dihydroxycholesterol

22(r),26-Dihydroxycholesterol

C27H46O3 (418.3447)


   

(25R)-3alpha,7alpha-dihydroxy-5beta-cholestan-26-al

(25R)-3alpha,7alpha-dihydroxy-5beta-cholestan-26-al

C27H46O3 (418.3447)


   

4beta,24S-dihydroxycholesterol

4beta,24S-dihydroxycholesterol

C27H46O3 (418.3447)


An oxysterol that is cholesterol which is substituted by hydroxy groups at positions 4beta and 24S.

   

7a,12a-Dihydroxy-5b-cholestan-3-one

7a,12a-Dihydroxy-5b-cholestan-3-one

C27H46O3 (418.3447)


   

17a,20a-Dihydroxycholesterol

17a,20a-Dihydroxycholesterol

C27H46O3 (418.3447)


   

N-Arachidonoyl Asparagine

N-Arachidonoyl Asparagine

C24H38N2O4 (418.2831)


   

8-Apo-b-caroten-8-ol

8-Apo-b-caroten-8-ol

C30H42O (418.3235)


   

Furost-5-ene-3beta,22,26-triol

Furost-5-ene-3beta,22,26-triol

C26H42O4 (418.3083)


   

[3-Carboxy-2-(13-carboxy-4-hydroxytridecanoyl)oxypropyl]-trimethylazanium

[3-Carboxy-2-(13-carboxy-4-hydroxytridecanoyl)oxypropyl]-trimethylazanium

C21H40NO7+ (418.2805)


   

[3-Carboxy-2-(13-carboxy-6-hydroxytridecanoyl)oxypropyl]-trimethylazanium

[3-Carboxy-2-(13-carboxy-6-hydroxytridecanoyl)oxypropyl]-trimethylazanium

C21H40NO7+ (418.2805)


   

[3-Carboxy-2-(13-carboxy-7-hydroxytridecanoyl)oxypropyl]-trimethylazanium

[3-Carboxy-2-(13-carboxy-7-hydroxytridecanoyl)oxypropyl]-trimethylazanium

C21H40NO7+ (418.2805)


   

[3-Carboxy-2-(13-carboxy-5-hydroxytridecanoyl)oxypropyl]-trimethylazanium

[3-Carboxy-2-(13-carboxy-5-hydroxytridecanoyl)oxypropyl]-trimethylazanium

C21H40NO7+ (418.2805)


   

[3-Carboxy-2-(13-carboxy-3-hydroxytridecanoyl)oxypropyl]-trimethylazanium

[3-Carboxy-2-(13-carboxy-3-hydroxytridecanoyl)oxypropyl]-trimethylazanium

C21H40NO7+ (418.2805)


   

Secosterol-A

Secosterol-A

C27H46O3 (418.3447)


   

beta-Citraurinene

beta-Citraurinene

C30H42O (418.3235)


   

3-Dehydro-6-deoxo-28-norteasterone

3-Dehydro-6-deoxo-28-norteasterone

C27H46O3 (418.3447)


   

16S,22S-dihydroxycholesterol

16S,22S-dihydroxycholesterol

C27H46O3 (418.3447)


   

Dihydroxycholesterol

Dihydroxycholesterol

C27H46O3 (418.3447)


   

N-eicosanoyl-taurine

N-eicosanoyl-taurine

C22H44NO4S- (418.2991)


   

(24S)-7alpha,24-dihydroxy-5beta-cholestan-3-one

(24S)-7alpha,24-dihydroxy-5beta-cholestan-3-one

C27H46O3 (418.3447)


7alpha,24-Dihydroxy-5beta-cholestan-3-one with S configuration at C-24.

   

(24S,25S)-cholest-5-en-3beta,24,26-triol

(24S,25S)-cholest-5-en-3beta,24,26-triol

C27H46O3 (418.3447)


An oxysterol that is cholesterol which is substituted by hydroxy groups at positions 24S and 27 and has S-configuration at position 25.

   
   

(3R,3aR,5bR,8S,9aR)-8,9a-dihydroxy-3a,5b-dimethyl-3-[(2R)-6-methylheptan-2-yl]-2,3,4,5,5a,6,7,8,9,10,10a,10b-dodecahydro-1H-cyclopenta[a]fluorene-10-carbaldehyde

(3R,3aR,5bR,8S,9aR)-8,9a-dihydroxy-3a,5b-dimethyl-3-[(2R)-6-methylheptan-2-yl]-2,3,4,5,5a,6,7,8,9,10,10a,10b-dodecahydro-1H-cyclopenta[a]fluorene-10-carbaldehyde

C27H46O3 (418.3447)


   

Di(2-nonyl) phthalate

Di(2-nonyl) phthalate

C26H42O4 (418.3083)


   

Di(2,6-dimethyl-4-heptyl) phthalate

Di(2,6-dimethyl-4-heptyl) phthalate

C26H42O4 (418.3083)


   

24R-Cholest-5-en-3beta,7-alpha,24-triol

24R-Cholest-5-en-3beta,7-alpha,24-triol

C27H46O3 (418.3447)


   

[1-hydroxy-3-[(5Z,8Z,11Z,14Z,17Z)-icosa-5,8,11,14,17-pentaenoxy]propan-2-yl] propanoate

[1-hydroxy-3-[(5Z,8Z,11Z,14Z,17Z)-icosa-5,8,11,14,17-pentaenoxy]propan-2-yl] propanoate

C26H42O4 (418.3083)


   

[1-hydroxy-3-[(3Z,6Z,9Z,12Z,15Z)-octadeca-3,6,9,12,15-pentaenoxy]propan-2-yl] pentanoate

[1-hydroxy-3-[(3Z,6Z,9Z,12Z,15Z)-octadeca-3,6,9,12,15-pentaenoxy]propan-2-yl] pentanoate

C26H42O4 (418.3083)


   

[3-carboxy-2-[(7E,9Z,11Z,13E,15E)-octadeca-7,9,11,13,15-pentaenoyl]oxypropyl]-trimethylazanium

[3-carboxy-2-[(7E,9Z,11Z,13E,15E)-octadeca-7,9,11,13,15-pentaenoyl]oxypropyl]-trimethylazanium

C25H40NO4+ (418.2957)


   

Fahfa 20:4/6:0

Fahfa 20:4/6:0

C26H42O4 (418.3083)


   

Fahfa 4:0/22:4

Fahfa 4:0/22:4

C26H42O4 (418.3083)


   

Fahfa 2:0/24:4

Fahfa 2:0/24:4

C26H42O4 (418.3083)


   

Fahfa 22:4/4:0

Fahfa 22:4/4:0

C26H42O4 (418.3083)


   

Fahfa 18:4/8:0

Fahfa 18:4/8:0

C26H42O4 (418.3083)


   

Fahfa 6:0/20:4

Fahfa 6:0/20:4

C26H42O4 (418.3083)


   

Fahfa 16:4/10:0

Fahfa 16:4/10:0

C26H42O4 (418.3083)


   

(2E,6E,10E,15E)-6,10-Bis(trimethylsilylmethyl)-2,6,10,14-hexadecatetraene

(2E,6E,10E,15E)-6,10-Bis(trimethylsilylmethyl)-2,6,10,14-hexadecatetraene

C26H50Si2 (418.3451)


   

2-[(12Z,15Z,18Z,21Z)-tetracosa-12,15,18,21-tetraenoyl]oxyacetic acid

2-[(12Z,15Z,18Z,21Z)-tetracosa-12,15,18,21-tetraenoyl]oxyacetic acid

C26H42O4 (418.3083)


   

[1-Carboxy-3-(3-dodecanoyloxy-2-hydroxypropoxy)propyl]-trimethylazanium

[1-Carboxy-3-(3-dodecanoyloxy-2-hydroxypropoxy)propyl]-trimethylazanium

C22H44NO6+ (418.3168)


   

[1-Carboxy-3-(2-octanoyloxy-3-propanoyloxypropoxy)propyl]-trimethylazanium

[1-Carboxy-3-(2-octanoyloxy-3-propanoyloxypropoxy)propyl]-trimethylazanium

C21H40NO7+ (418.2805)


   

[3-(3-Butanoyloxy-2-heptanoyloxypropoxy)-1-carboxypropyl]-trimethylazanium

[3-(3-Butanoyloxy-2-heptanoyloxypropoxy)-1-carboxypropyl]-trimethylazanium

C21H40NO7+ (418.2805)


   

[3-(3-Acetyloxy-2-nonanoyloxypropoxy)-1-carboxypropyl]-trimethylazanium

[3-(3-Acetyloxy-2-nonanoyloxypropoxy)-1-carboxypropyl]-trimethylazanium

C21H40NO7+ (418.2805)


   

[1-Carboxy-3-(2-hexanoyloxy-3-pentanoyloxypropoxy)propyl]-trimethylazanium

[1-Carboxy-3-(2-hexanoyloxy-3-pentanoyloxypropoxy)propyl]-trimethylazanium

C21H40NO7+ (418.2805)


   

7alpha,27-dihydroxycholesterol

7alpha,27-dihydroxycholesterol

C27H46O3 (418.3447)


   

(20R,22R)-20,22-dihydroxycholesterol

(20R,22R)-20,22-dihydroxycholesterol

C27H46O3 (418.3447)


An oxysterol that is cholesterol substituted by hydroxy groups at positions 20 and 22 (the 20R,22R-stereoisomer).

   

7alpha,12alpha-Dihydroxy-5beta-cholestan-3-one

7alpha,12alpha-Dihydroxy-5beta-cholestan-3-one

C27H46O3 (418.3447)


A 3-oxo-5beta-steroid that is 5beta-cholestan-3-one bearing two additional hydroxy substituents at positions 7alpha and 12alpha.

   

3alpha,7alpha-dihydroxy-5beta-cholestan-26-al

3alpha,7alpha-dihydroxy-5beta-cholestan-26-al

C27H46O3 (418.3447)


   

(20S)-Cholesta-5-ene-3beta,17,20-triol

(20S)-Cholesta-5-ene-3beta,17,20-triol

C27H46O3 (418.3447)


   

(25R)-7alpha,26-dihydroxycholesterol

(25R)-7alpha,26-dihydroxycholesterol

C27H46O3 (418.3447)


A 7alpha,26-dihydroxycholesterol that has R configuration at position 25.

   

UNII:19ND350H65

Bis(3,5,5-trimethylhexyl) phthalate

C26H42O4 (418.3083)


   

20a,22b-Dihydroxycholesterol

20a,22b-Dihydroxycholesterol

C27H46O3 (418.3447)


   

7alpha,26-dihydroxy-5beta-cholestan-3-one

7alpha,26-dihydroxy-5beta-cholestan-3-one

C27H46O3 (418.3447)


   

11-Carboxy-alpha-chromanol

11-Carboxy-alpha-chromanol

C26H42O4 (418.3083)


   

(25R)-4beta,26-dihydroxycholesterol

(25R)-4beta,26-dihydroxycholesterol

C27H46O3 (418.3447)


An oxysterol that is cholesterol which is substituted by hydroxy groups at 4beta and 26 positions and has R-configuration at position 25.

   

7alpha,24-dihydroxy-5beta-cholestan-3-one

7alpha,24-dihydroxy-5beta-cholestan-3-one

C27H46O3 (418.3447)


   

7beta,27-dihydroxycholesterol

7beta,27-dihydroxycholesterol

C27H46O3 (418.3447)


   

7beta,25-dihydroxycholesterol

7beta,25-dihydroxycholesterol

C27H46O3 (418.3447)


   

(20R)-17alpha,20-dihydroxycholesterol

(20R)-17alpha,20-dihydroxycholesterol

C27H46O3 (418.3447)


An oxysterol that is cholesterol substituted by hydroxy groups at positions 17 and 20 (the 20R-stereoisomer).

   

24-northornasterol A

24-northornasterol A

C26H42O4 (418.3083)


   

N-icosanoyltaurine(1-)

N-icosanoyltaurine(1-)

C22H44NO4S (418.2991)


A fatty acid-taurine conjugate obtained by deprotonation of the sulfonate group of N-icosanoyltaurine; major species at pH 7.3.

   

3beta-hydroxycholest-4-ene-6beta-hydroperoxide

3beta-hydroxycholest-4-ene-6beta-hydroperoxide

C27H46O3 (418.3447)


   

3beta-hydroxycholest-4-ene-6alpha-hydroperoxide

3beta-hydroxycholest-4-ene-6alpha-hydroperoxide

C27H46O3 (418.3447)


   

16beta,20S-dihydroxy-5-alpha-cholestan-3-one

16beta,20S-dihydroxy-5-alpha-cholestan-3-one

C27H46O3 (418.3447)


   

(24R)-1alpha,24-dihydroxy-22-oxavitamin D3

(24R)-1alpha,24-dihydroxy-22-oxavitamin D3

C26H42O4 (418.3083)


A hydroxy seco-steroid that is calciol with C-22 replaced with an oxygen atom, and additional hydroxy groups at positions 1 and 24.

   

16alpha,27-dihydroxycholesterol

16alpha,27-dihydroxycholesterol

C27H46O3 (418.3447)


   

1-O-(2R-methoxy-4Z,7Z,10Z,13Z,16Z,19Z-docosahexaenyl)-sn-glycerol

1-O-(2R-methoxy-4Z,7Z,10Z,13Z,16Z,19Z-docosahexaenyl)-sn-glycerol

C26H42O4 (418.3083)


   

(24S)-7alpha,24-Dihydroxycholesterol

(24S)-7alpha,24-Dihydroxycholesterol

C27H46O3 (418.3447)


A 7alpha,24-dihydroxycholesterol in which has S configuration at position 24.

   

7alpha,26-Dihydroxycholesterol

7alpha,26-Dihydroxycholesterol

C27H46O3 (418.3447)


An oxysterol that is cholesterol which is substituted by hydroxy groups at the 7alpha and 26 positions.

   

(16S,22S)-dihydroxycholesterol

(16S,22S)-dihydroxycholesterol

C27H46O3 (418.3447)


A C27-steroid that is cholesterol carrying a hydroxy group at position 16S and 22S.

   

(7alpha,22R)-dihydroxycholesterol

(7alpha,22R)-dihydroxycholesterol

C27H46O3 (418.3447)


An oxysterol that is cholesterol which is substituted by hydroxy groups at positions 7alpha and 22R.

   

DG(23:5)

DG(12:1(1)_11:4)

C26H42O4 (418.3083)


Provides by LipidSearch Vendor. © Copyright 2006-2024 Thermo Fisher Scientific Inc. All rights reserved

   

Hydroxyheptacosatetraenoic acid

Hydroxyheptacosatetraenoic acid

C27H46O3 (418.3447)


   

NA-Arg 18:4(6Z,9Z,12Z,15Z)

NA-Arg 18:4(6Z,9Z,12Z,15Z)

C23H38N4O3 (418.2944)


   

NA-Asn 20:4(5Z,8Z,11Z,14Z)

NA-Asn 20:4(5Z,8Z,11Z,14Z)

C24H38N2O4 (418.2831)


   

NA-Orn 20:4(5Z,8Z,11Z,14Z)

NA-Orn 20:4(5Z,8Z,11Z,14Z)

C25H42N2O3 (418.3195)


   

NA-Tryptamine 18:4(6Z,9Z,12Z,15Z)

NA-Tryptamine 18:4(6Z,9Z,12Z,15Z)

C28H38N2O (418.2984)


   

FAHFA 10:0/O-16:4

FAHFA 10:0/O-16:4

C26H42O4 (418.3083)


   

FAHFA 10:1/O-16:3

FAHFA 10:1/O-16:3

C26H42O4 (418.3083)


   

FAHFA 10:2/O-16:2

FAHFA 10:2/O-16:2

C26H42O4 (418.3083)


   

FAHFA 10:3/O-16:1

FAHFA 10:3/O-16:1

C26H42O4 (418.3083)


   

FAHFA 11:0/O-15:4

FAHFA 11:0/O-15:4

C26H42O4 (418.3083)


   

FAHFA 11:1/O-15:3

FAHFA 11:1/O-15:3

C26H42O4 (418.3083)


   

FAHFA 11:2/O-15:2

FAHFA 11:2/O-15:2

C26H42O4 (418.3083)


   

FAHFA 11:3/O-15:1

FAHFA 11:3/O-15:1

C26H42O4 (418.3083)


   

FAHFA 12:0/O-14:4

FAHFA 12:0/O-14:4

C26H42O4 (418.3083)


   

FAHFA 12:1/O-14:3

FAHFA 12:1/O-14:3

C26H42O4 (418.3083)


   

FAHFA 12:2/O-14:2

FAHFA 12:2/O-14:2

C26H42O4 (418.3083)


   

FAHFA 12:3/O-14:1

FAHFA 12:3/O-14:1

C26H42O4 (418.3083)


   

FAHFA 12:4/O-14:0

FAHFA 12:4/O-14:0

C26H42O4 (418.3083)


   

FAHFA 13:0/O-13:4

FAHFA 13:0/O-13:4

C26H42O4 (418.3083)


   

FAHFA 13:1/O-13:3

FAHFA 13:1/O-13:3

C26H42O4 (418.3083)


   

FAHFA 13:2/O-13:2

FAHFA 13:2/O-13:2

C26H42O4 (418.3083)


   

FAHFA 13:3/O-13:1

FAHFA 13:3/O-13:1

C26H42O4 (418.3083)


   

FAHFA 13:4/O-13:0

FAHFA 13:4/O-13:0

C26H42O4 (418.3083)


   

FAHFA 14:0/O-12:4

FAHFA 14:0/O-12:4

C26H42O4 (418.3083)


   

FAHFA 14:1/O-12:3

FAHFA 14:1/O-12:3

C26H42O4 (418.3083)


   

FAHFA 14:2/O-12:2

FAHFA 14:2/O-12:2

C26H42O4 (418.3083)


   

FAHFA 14:3/O-12:1

FAHFA 14:3/O-12:1

C26H42O4 (418.3083)


   

FAHFA 14:4/O-12:0

FAHFA 14:4/O-12:0

C26H42O4 (418.3083)


   

FAHFA 15:1/O-11:3

FAHFA 15:1/O-11:3

C26H42O4 (418.3083)


   

FAHFA 15:2/O-11:2

FAHFA 15:2/O-11:2

C26H42O4 (418.3083)


   

FAHFA 15:3/O-11:1

FAHFA 15:3/O-11:1

C26H42O4 (418.3083)


   

FAHFA 15:4/O-11:0

FAHFA 15:4/O-11:0

C26H42O4 (418.3083)


   

FAHFA 16:1/O-10:3

FAHFA 16:1/O-10:3

C26H42O4 (418.3083)


   

FAHFA 16:2/O-10:2

FAHFA 16:2/O-10:2

C26H42O4 (418.3083)


   

FAHFA 16:3/O-10:1

FAHFA 16:3/O-10:1

C26H42O4 (418.3083)


   

FAHFA 16:4/O-10:0

FAHFA 16:4/O-10:0

C26H42O4 (418.3083)


   

FAHFA 17:1/O-9:3

FAHFA 17:1/O-9:3

C26H42O4 (418.3083)


   

FAHFA 17:2/O-9:2

FAHFA 17:2/O-9:2

C26H42O4 (418.3083)


   

FAHFA 17:3/O-9:1

FAHFA 17:3/O-9:1

C26H42O4 (418.3083)


   

FAHFA 17:4/O-9:0

FAHFA 17:4/O-9:0

C26H42O4 (418.3083)


   

FAHFA 18:2/O-8:2

FAHFA 18:2/O-8:2

C26H42O4 (418.3083)


   

FAHFA 18:3/O-8:1

FAHFA 18:3/O-8:1

C26H42O4 (418.3083)


   

FAHFA 18:4/O-8:0

FAHFA 18:4/O-8:0

C26H42O4 (418.3083)


   

FAHFA 20:4(5Z,8Z,11Z,14Z)/3O-6:0

FAHFA 20:4(5Z,8Z,11Z,14Z)/3O-6:0

C26H42O4 (418.3083)


   

FAHFA 26:4;O

FAHFA 26:4;O

C26H42O4 (418.3083)


   

FAHFA 8:0/O-18:4

FAHFA 8:0/O-18:4

C26H42O4 (418.3083)


   

FAHFA 8:1/O-18:3

FAHFA 8:1/O-18:3

C26H42O4 (418.3083)


   

FAHFA 8:2/O-18:2

FAHFA 8:2/O-18:2

C26H42O4 (418.3083)


   

FAHFA 9:0/O-17:4

FAHFA 9:0/O-17:4

C26H42O4 (418.3083)


   

FAHFA 9:1/O-17:3

FAHFA 9:1/O-17:3

C26H42O4 (418.3083)


   

FAHFA 9:2/O-17:2

FAHFA 9:2/O-17:2

C26H42O4 (418.3083)


   

FAHFA 9:3/O-17:1

FAHFA 9:3/O-17:1

C26H42O4 (418.3083)


   

Dihydroxycholestanal

Dihydroxycholestanal

C27H46O3 (418.3447)


   

Dihydroxycholestanone

Dihydroxycholestanone

C27H46O3 (418.3447)


   
   

1-(2r)-2-ethylheptyl 2-(2s)-2-ethylheptyl phthalate

1-(2r)-2-ethylheptyl 2-(2s)-2-ethylheptyl phthalate

C26H42O4 (418.3083)


   

(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl hexadecanoate

(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl hexadecanoate

C22H42O7 (418.293)


   

(1r,3ar,3bs,5as,7s,9ar,9br,11ar)-9a,11a-dimethyl-1-[(2r)-6-methylheptan-2-yl]-1h,2h,3h,3ah,6h,7h,8h,9h,9bh,10h,11h-cyclopenta[a]phenanthrene-3b,5a,7-triol

(1r,3ar,3bs,5as,7s,9ar,9br,11ar)-9a,11a-dimethyl-1-[(2r)-6-methylheptan-2-yl]-1h,2h,3h,3ah,6h,7h,8h,9h,9bh,10h,11h-cyclopenta[a]phenanthrene-3b,5a,7-triol

C27H46O3 (418.3447)


   

5a,7-dihydroxy-9a,11a-dimethyl-1-(6-methylheptan-2-yl)-dodecahydro-1h-cyclopenta[a]phenanthren-5-one

5a,7-dihydroxy-9a,11a-dimethyl-1-(6-methylheptan-2-yl)-dodecahydro-1h-cyclopenta[a]phenanthren-5-one

C27H46O3 (418.3447)


   

(4e,6e,8e,10e,12e,14e,16e,18e,20e)-2,6,10,14,19,23-hexamethyltetracosa-4,6,8,10,12,14,16,18,20,22-decaen-2-ol

(4e,6e,8e,10e,12e,14e,16e,18e,20e)-2,6,10,14,19,23-hexamethyltetracosa-4,6,8,10,12,14,16,18,20,22-decaen-2-ol

C30H42O (418.3235)


   

methyl (5z,8e,10e,12r,14z)-12-[(3-methylbutanoyl)oxy]icosa-5,8,10,14-tetraenoate

methyl (5z,8e,10e,12r,14z)-12-[(3-methylbutanoyl)oxy]icosa-5,8,10,14-tetraenoate

C26H42O4 (418.3083)


   

6-amino-15-[1-(dimethylamino)ethyl]-7-(hydroxymethyl)-7,12,16-trimethylpentacyclo[9.7.0.0¹,³.0³,⁸.0¹²,¹⁶]octadecan-14-ol

6-amino-15-[1-(dimethylamino)ethyl]-7-(hydroxymethyl)-7,12,16-trimethylpentacyclo[9.7.0.0¹,³.0³,⁸.0¹²,¹⁶]octadecan-14-ol

C26H46N2O2 (418.3559)


   

(1s,2r,5s,7s,9r,10r,11s,12s,15r,16r)-2,16-dimethyl-15-[(2r)-6-methylheptan-2-yl]-8-oxapentacyclo[9.7.0.0²,⁷.0⁷,⁹.0¹²,¹⁶]octadecane-5,10-diol

(1s,2r,5s,7s,9r,10r,11s,12s,15r,16r)-2,16-dimethyl-15-[(2r)-6-methylheptan-2-yl]-8-oxapentacyclo[9.7.0.0²,⁷.0⁷,⁹.0¹²,¹⁶]octadecane-5,10-diol

C27H46O3 (418.3447)


   

1,3-dihydroxypropan-2-yl (3r,6s)-3,6-dihydroxyicosanoate

1,3-dihydroxypropan-2-yl (3r,6s)-3,6-dihydroxyicosanoate

C23H46O6 (418.3294)


   

(1r,3r,5s,5as,7s,9ar,9br,11ar)-1-[(2r,3e,5r)-6-hydroxy-5-methylhex-3-en-2-yl]-9a,11a-dimethyl-1h,2h,3h,4h,5h,5ah,6h,7h,8h,9h,9bh,10h,11h-cyclopenta[a]phenanthrene-3,5,7-triol

(1r,3r,5s,5as,7s,9ar,9br,11ar)-1-[(2r,3e,5r)-6-hydroxy-5-methylhex-3-en-2-yl]-9a,11a-dimethyl-1h,2h,3h,4h,5h,5ah,6h,7h,8h,9h,9bh,10h,11h-cyclopenta[a]phenanthrene-3,5,7-triol

C26H42O4 (418.3083)


   

4-hydroxy-2-tridecyl-1,7-dioxadispiro[5.1.5⁸.2⁶]pentadeca-9,12-dien-11-one

4-hydroxy-2-tridecyl-1,7-dioxadispiro[5.1.5⁸.2⁶]pentadeca-9,12-dien-11-one

C26H42O4 (418.3083)


   

n-({[(2r,4ar,7s,8as,10as)-7-ethenyl-1,1,4a,7-tetramethyl-3,4,6,8,8a,9,10,10a-octahydro-2h-phenanthren-2-yl]oxy}(hydroxy)methylidene)-2-hydroxyethanecarbamimidic acid

n-({[(2r,4ar,7s,8as,10as)-7-ethenyl-1,1,4a,7-tetramethyl-3,4,6,8,8a,9,10,10a-octahydro-2h-phenanthren-2-yl]oxy}(hydroxy)methylidene)-2-hydroxyethanecarbamimidic acid

C24H38N2O4 (418.2831)


   

(2e,4e,6e,8e,10e,12e,14e,16e,18e)-2,6,10,15,19,23-hexamethyltetracosa-2,4,6,8,10,12,14,16,18,22-decaen-1-ol

(2e,4e,6e,8e,10e,12e,14e,16e,18e)-2,6,10,15,19,23-hexamethyltetracosa-2,4,6,8,10,12,14,16,18,22-decaen-1-ol

C30H42O (418.3235)


   

3-hydroxy-3,7,11,15-tetramethylhexadecyl benzoate

3-hydroxy-3,7,11,15-tetramethylhexadecyl benzoate

C27H46O3 (418.3447)


   

[(3s,4s,6r)-6-[(2r,6s)-2,6-dimethyl-10-phenyldecyl]-4,6-dimethyl-1,2-dioxan-3-yl]acetic acid

[(3s,4s,6r)-6-[(2r,6s)-2,6-dimethyl-10-phenyldecyl]-4,6-dimethyl-1,2-dioxan-3-yl]acetic acid

C26H42O4 (418.3083)


   

1,3-dihydroxypropan-2-yl 3,9-dihydroxyicosanoate

1,3-dihydroxypropan-2-yl 3,9-dihydroxyicosanoate

C23H46O6 (418.3294)


   

(1r)-3,5,5-trimethyl-4-[(1e,3e,5e,7e,9e,11e,13e)-3,7,12,16-tetramethylheptadeca-1,3,5,7,9,11,13,15-octaen-1-yl]cyclohex-3-en-1-ol

(1r)-3,5,5-trimethyl-4-[(1e,3e,5e,7e,9e,11e,13e)-3,7,12,16-tetramethylheptadeca-1,3,5,7,9,11,13,15-octaen-1-yl]cyclohex-3-en-1-ol

C30H42O (418.3235)


   

1-(3,5-dihydroxyphenyl)henicosan-2-one

1-(3,5-dihydroxyphenyl)henicosan-2-one

C27H46O3 (418.3447)


   

(1r,3as,3bs,5r,5ar,7r,9as,11ar)-1-[(2r,4s)-4-hydroxy-6-methylheptan-2-yl]-9a,11a-dimethyl-1h,2h,3h,3ah,3bh,4h,5h,5ah,6h,7h,8h,9h,11h-cyclopenta[a]phenanthrene-5,7-diol

(1r,3as,3bs,5r,5ar,7r,9as,11ar)-1-[(2r,4s)-4-hydroxy-6-methylheptan-2-yl]-9a,11a-dimethyl-1h,2h,3h,3ah,3bh,4h,5h,5ah,6h,7h,8h,9h,11h-cyclopenta[a]phenanthrene-5,7-diol

C27H46O3 (418.3447)


   

aculeatin d

NA

C26H42O4 (418.3083)


{"Ingredient_id": "HBIN014646","Ingredient_name": "aculeatin d","Alias": "NA","Ingredient_formula": "C26H42O4","Ingredient_Smile": "CCCCCCCCCCCCCC1CC(CC2(O1)CCC3(O2)C=CC(=O)C=C3)O","Ingredient_weight": "NA","OB_score": "NA","CAS_id": "NA","SymMap_id": "NA","TCMID_id": "589","TCMSP_id": "NA","TCM_ID_id": "NA","PubChem_id": "NA","DrugBank_id": "NA"}

   

(1s)-3,5,5-trimethyl-4-[(1e,3e,5e,7e,9e,11e,13e)-3,7,12,16-tetramethylheptadeca-1,3,5,7,9,11,13,15-octaen-1-yl]cyclohex-3-en-1-ol

(1s)-3,5,5-trimethyl-4-[(1e,3e,5e,7e,9e,11e,13e)-3,7,12,16-tetramethylheptadeca-1,3,5,7,9,11,13,15-octaen-1-yl]cyclohex-3-en-1-ol

C30H42O (418.3235)


   

2,5-dihydroxy-3-methyl-6-[(14z)-nonadec-14-en-1-yl]cyclohexa-2,5-diene-1,4-dione

2,5-dihydroxy-3-methyl-6-[(14z)-nonadec-14-en-1-yl]cyclohexa-2,5-diene-1,4-dione

C26H42O4 (418.3083)


   

(1r,3br,5s,5as,7s,9ar,9bs,11ar)-1-[(2s,5r)-5-hydroxy-6-methylheptan-2-yl]-9a,11a-dimethyl-1h,2h,3bh,4h,5h,5ah,6h,7h,8h,9h,9bh,10h,11h-cyclopenta[a]phenanthrene-5,7-diol

(1r,3br,5s,5as,7s,9ar,9bs,11ar)-1-[(2s,5r)-5-hydroxy-6-methylheptan-2-yl]-9a,11a-dimethyl-1h,2h,3bh,4h,5h,5ah,6h,7h,8h,9h,9bh,10h,11h-cyclopenta[a]phenanthrene-5,7-diol

C27H46O3 (418.3447)


   

(1r,2r,3as,3bs,7s,9ar,9bs,11as)-1-[(2s,3r)-3-hydroxy-6-methylheptan-2-yl]-9a,11a-dimethyl-1h,2h,3h,3ah,3bh,4h,6h,7h,8h,9h,9bh,10h,11h-cyclopenta[a]phenanthrene-2,7-diol

(1r,2r,3as,3bs,7s,9ar,9bs,11as)-1-[(2s,3r)-3-hydroxy-6-methylheptan-2-yl]-9a,11a-dimethyl-1h,2h,3h,3ah,3bh,4h,6h,7h,8h,9h,9bh,10h,11h-cyclopenta[a]phenanthrene-2,7-diol

C27H46O3 (418.3447)


   

(2z)-3-(4-hydroxy-3-methoxyphenyl)prop-2-en-1-yl hexadecanoate

(2z)-3-(4-hydroxy-3-methoxyphenyl)prop-2-en-1-yl hexadecanoate

C26H42O4 (418.3083)


   

2,5-dihydroxy-3-methyl-6-[(14e)-nonadec-14-en-1-yl]cyclohexa-2,5-diene-1,4-dione

2,5-dihydroxy-3-methyl-6-[(14e)-nonadec-14-en-1-yl]cyclohexa-2,5-diene-1,4-dione

C26H42O4 (418.3083)


   

hexadecyl (2e)-3-(4-hydroxy-3-methoxyphenyl)prop-2-enoate

hexadecyl (2e)-3-(4-hydroxy-3-methoxyphenyl)prop-2-enoate

C26H42O4 (418.3083)


   

4-hydroxy-2-tridecyl-1,14-dioxadispiro[5.1.5⁸.2⁶]pentadeca-9,12-dien-11-one

4-hydroxy-2-tridecyl-1,14-dioxadispiro[5.1.5⁸.2⁶]pentadeca-9,12-dien-11-one

C26H42O4 (418.3083)


   

(1r,3s,5z)-5-{2-[(1s,3as,4e,7as)-1-[(1s)-1-[(2r)-2-hydroxy-3-methylbutoxy]ethyl]-7a-methyl-hexahydro-1h-inden-4-ylidene]ethylidene}-4-methylidenecyclohexane-1,3-diol

(1r,3s,5z)-5-{2-[(1s,3as,4e,7as)-1-[(1s)-1-[(2r)-2-hydroxy-3-methylbutoxy]ethyl]-7a-methyl-hexahydro-1h-inden-4-ylidene]ethylidene}-4-methylidenecyclohexane-1,3-diol

C26H42O4 (418.3083)


   

(1r,3ar,3br,4r,5s,5as,7r,9ar,9br,11ar)-9a,11a-dimethyl-1-[(2r)-6-methylhept-5-en-2-yl]-tetradecahydro-1h-cyclopenta[a]phenanthrene-4,5,7-triol

(1r,3ar,3br,4r,5s,5as,7r,9ar,9br,11ar)-9a,11a-dimethyl-1-[(2r)-6-methylhept-5-en-2-yl]-tetradecahydro-1h-cyclopenta[a]phenanthrene-4,5,7-triol

C27H46O3 (418.3447)


   

1-(6-hydroxy-5-methylhex-3-en-2-yl)-9a,11a-dimethyl-1h,2h,3h,4h,5h,5ah,6h,7h,8h,9h,9bh,10h,11h-cyclopenta[a]phenanthrene-3,5,7-triol

1-(6-hydroxy-5-methylhex-3-en-2-yl)-9a,11a-dimethyl-1h,2h,3h,4h,5h,5ah,6h,7h,8h,9h,9bh,10h,11h-cyclopenta[a]phenanthrene-3,5,7-triol

C26H42O4 (418.3083)


   

(2s,6s,8as)-6-hydroxy-2-[(1s,2r,3r)-2-(2-hydroxyethyl)-2-methyl-3-[(2r)-6-methylheptan-2-yl]cyclopentyl]-8a-methyl-2,3,5,6,7,8-hexahydronaphthalen-1-one

(2s,6s,8as)-6-hydroxy-2-[(1s,2r,3r)-2-(2-hydroxyethyl)-2-methyl-3-[(2r)-6-methylheptan-2-yl]cyclopentyl]-8a-methyl-2,3,5,6,7,8-hexahydronaphthalen-1-one

C27H46O3 (418.3447)


   

5,9',13'-trimethyl-5'-oxaspiro[oxane-2,6'-pentacyclo[10.8.0.0²,⁹.0⁴,⁸.0¹³,¹⁸]icosane]-3',16'-diol

5,9',13'-trimethyl-5'-oxaspiro[oxane-2,6'-pentacyclo[10.8.0.0²,⁹.0⁴,⁸.0¹³,¹⁸]icosane]-3',16'-diol

C26H42O4 (418.3083)


   

1,2-bis(2-ethylheptyl) phthalate

1,2-bis(2-ethylheptyl) phthalate

C26H42O4 (418.3083)


   

1-[1-({7-isopropyl-2,10-dimethylspiro[4.5]dec-1-en-6-yl}-c-hydroxycarbonimidoyl)-1-methylethyl]-5-oxopyrrolidine-2-carboxylic acid

1-[1-({7-isopropyl-2,10-dimethylspiro[4.5]dec-1-en-6-yl}-c-hydroxycarbonimidoyl)-1-methylethyl]-5-oxopyrrolidine-2-carboxylic acid

C24H38N2O4 (418.2831)


   

3,5,5-trimethyl-4-(3,7,12,16-tetramethylheptadeca-1,3,5,7,9,11,13,15-octaen-1-yl)cyclohex-3-en-1-ol

3,5,5-trimethyl-4-(3,7,12,16-tetramethylheptadeca-1,3,5,7,9,11,13,15-octaen-1-yl)cyclohex-3-en-1-ol

C30H42O (418.3235)


   

1,3-dihydroxypropan-2-yl 3,7-dihydroxyicosanoate

1,3-dihydroxypropan-2-yl 3,7-dihydroxyicosanoate

C23H46O6 (418.3294)


   

(4e,6e,8e,10e,12e,14e,16e)-2,6,11,15-tetramethyl-17-(2,6,6-trimethylcyclohex-1-en-1-yl)heptadeca-2,4,6,8,10,12,14,16-octaen-1-ol

(4e,6e,8e,10e,12e,14e,16e)-2,6,11,15-tetramethyl-17-(2,6,6-trimethylcyclohex-1-en-1-yl)heptadeca-2,4,6,8,10,12,14,16-octaen-1-ol

C30H42O (418.3235)


   

[4,6-dimethyl-6-(2-methyl-11-phenylundecyl)-1,2-dioxan-3-yl]acetic acid

[4,6-dimethyl-6-(2-methyl-11-phenylundecyl)-1,2-dioxan-3-yl]acetic acid

C26H42O4 (418.3083)


   

[(3s,4s,6r)-4,6-dimethyl-6-[(2r)-2-methyl-11-phenylundecyl]-1,2-dioxan-3-yl]acetic acid

[(3s,4s,6r)-4,6-dimethyl-6-[(2r)-2-methyl-11-phenylundecyl]-1,2-dioxan-3-yl]acetic acid

C26H42O4 (418.3083)


   

(1r,3as,5ar,9ar,9bs,11ar)-5a,7-dihydroxy-9a,11a-dimethyl-1-[(2r)-6-methylheptan-2-yl]-dodecahydro-1h-cyclopenta[a]phenanthren-5-one

(1r,3as,5ar,9ar,9bs,11ar)-5a,7-dihydroxy-9a,11a-dimethyl-1-[(2r)-6-methylheptan-2-yl]-dodecahydro-1h-cyclopenta[a]phenanthren-5-one

C27H46O3 (418.3447)


   

(1s,3r,6s,7r,8r,11s,12s,14r,15s,16r)-6-amino-15-[(1s)-1-(dimethylamino)ethyl]-7-(hydroxymethyl)-7,12,16-trimethylpentacyclo[9.7.0.0¹,³.0³,⁸.0¹²,¹⁶]octadecan-14-ol

(1s,3r,6s,7r,8r,11s,12s,14r,15s,16r)-6-amino-15-[(1s)-1-(dimethylamino)ethyl]-7-(hydroxymethyl)-7,12,16-trimethylpentacyclo[9.7.0.0¹,³.0³,⁸.0¹²,¹⁶]octadecan-14-ol

C26H46N2O2 (418.3559)


   

9a,11a-dimethyl-1-(6-methylhept-5-en-2-yl)-tetradecahydro-1h-cyclopenta[a]phenanthrene-4,5,7-triol

9a,11a-dimethyl-1-(6-methylhept-5-en-2-yl)-tetradecahydro-1h-cyclopenta[a]phenanthrene-4,5,7-triol

C27H46O3 (418.3447)


   

(1r,2s,3as,3br,5as,9as,9bs,11as)-2-hydroxy-1-[(2s)-2-hydroxy-6-methylheptan-2-yl]-9a,11a-dimethyl-tetradecahydrocyclopenta[a]phenanthren-7-one

(1r,2s,3as,3br,5as,9as,9bs,11as)-2-hydroxy-1-[(2s)-2-hydroxy-6-methylheptan-2-yl]-9a,11a-dimethyl-tetradecahydrocyclopenta[a]phenanthren-7-one

C27H46O3 (418.3447)


   

(1r,2s,3as,3bs,7s,9ar,9bs,11as)-1-[(2r)-2-hydroxy-6-methylheptan-2-yl]-9a,11a-dimethyl-1h,2h,3h,3ah,3bh,4h,6h,7h,8h,9h,9bh,10h,11h-cyclopenta[a]phenanthrene-2,7-diol

(1r,2s,3as,3bs,7s,9ar,9bs,11as)-1-[(2r)-2-hydroxy-6-methylheptan-2-yl]-9a,11a-dimethyl-1h,2h,3h,3ah,3bh,4h,6h,7h,8h,9h,9bh,10h,11h-cyclopenta[a]phenanthrene-2,7-diol

C27H46O3 (418.3447)


   

3-(4-hydroxy-3-methoxyphenyl)prop-2-en-1-yl hexadecanoate

3-(4-hydroxy-3-methoxyphenyl)prop-2-en-1-yl hexadecanoate

C26H42O4 (418.3083)


   

hexadecyl (2e)-3-(2-hydroxy-4-methoxyphenyl)prop-2-enoate

hexadecyl (2e)-3-(2-hydroxy-4-methoxyphenyl)prop-2-enoate

C26H42O4 (418.3083)


   

2-hydroxy-1-(2-hydroxy-6-methylheptan-2-yl)-9a,11a-dimethyl-tetradecahydrocyclopenta[a]phenanthren-7-one

2-hydroxy-1-(2-hydroxy-6-methylheptan-2-yl)-9a,11a-dimethyl-tetradecahydrocyclopenta[a]phenanthren-7-one

C27H46O3 (418.3447)


   

2,5-dihydroxy-3-methyl-6-(nonadec-14-en-1-yl)cyclohexa-2,5-diene-1,4-dione

2,5-dihydroxy-3-methyl-6-(nonadec-14-en-1-yl)cyclohexa-2,5-diene-1,4-dione

C26H42O4 (418.3083)


   

(3r,7s,11s)-3-hydroxy-3,7,11,15-tetramethylhexadecyl benzoate

(3r,7s,11s)-3-hydroxy-3,7,11,15-tetramethylhexadecyl benzoate

C27H46O3 (418.3447)


   

9a-(hydroxymethyl)-11a-methyl-1-(6-methylheptan-2-yl)-1h,2h,3h,3ah,3bh,4h,6h,7h,8h,9h,9bh,10h,11h-cyclopenta[a]phenanthrene-4,7-diol

9a-(hydroxymethyl)-11a-methyl-1-(6-methylheptan-2-yl)-1h,2h,3h,3ah,3bh,4h,6h,7h,8h,9h,9bh,10h,11h-cyclopenta[a]phenanthrene-4,7-diol

C27H46O3 (418.3447)


   

(4r)-5-hydroxy-4-{3-[(1r,6r)-2,2,6-trimethylcyclohexyl]propyl}pentyl 2,6,6-trimethylcyclohexa-1,3-diene-1-carboxylate

(4r)-5-hydroxy-4-{3-[(1r,6r)-2,2,6-trimethylcyclohexyl]propyl}pentyl 2,6,6-trimethylcyclohexa-1,3-diene-1-carboxylate

C27H46O3 (418.3447)


   

14-(hydroxymethyl)-14-methoxy-5,5,9-trimethyltetracyclo[11.2.1.0¹,¹⁰.0⁴,⁹]hexadecan-6-yl 2-methylbut-2-enoate

14-(hydroxymethyl)-14-methoxy-5,5,9-trimethyltetracyclo[11.2.1.0¹,¹⁰.0⁴,⁹]hexadecan-6-yl 2-methylbut-2-enoate

C26H42O4 (418.3083)


   

(4s,5e,8r,11s,12s,13r,15s,16r)-8,11,12,13,15,16-hexahydroxy-4,8,12,16-tetramethyloctadec-5-en-7-one

(4s,5e,8r,11s,12s,13r,15s,16r)-8,11,12,13,15,16-hexahydroxy-4,8,12,16-tetramethyloctadec-5-en-7-one

C22H42O7 (418.293)


   

1,3-dihydroxypropan-2-yl (3r,8r)-3,8-dihydroxyicosanoate

1,3-dihydroxypropan-2-yl (3r,8r)-3,8-dihydroxyicosanoate

C23H46O6 (418.3294)


   

n-{[(7-ethenyl-1,1,4a,7-tetramethyl-3,4,6,8,8a,9,10,10a-octahydro-2h-phenanthren-2-yl)oxy](hydroxy)methylidene}-2-hydroxyethanecarbamimidic acid

n-{[(7-ethenyl-1,1,4a,7-tetramethyl-3,4,6,8,8a,9,10,10a-octahydro-2h-phenanthren-2-yl)oxy](hydroxy)methylidene}-2-hydroxyethanecarbamimidic acid

C24H38N2O4 (418.2831)


   

(1r,3as,3bs,6r,7s,9ar,9bs,11as)-1-[(2s,3r)-3-hydroxy-6-methylheptan-2-yl]-9a,11a-dimethyl-1h,2h,3h,3ah,3bh,4h,6h,7h,8h,9h,9bh,10h,11h-cyclopenta[a]phenanthrene-6,7-diol

(1r,3as,3bs,6r,7s,9ar,9bs,11as)-1-[(2s,3r)-3-hydroxy-6-methylheptan-2-yl]-9a,11a-dimethyl-1h,2h,3h,3ah,3bh,4h,6h,7h,8h,9h,9bh,10h,11h-cyclopenta[a]phenanthrene-6,7-diol

C27H46O3 (418.3447)


   

(2r,4r,6s)-4-hydroxy-2-tridecyl-1,7-dioxadispiro[5.1.5⁸.2⁶]pentadeca-9,12-dien-11-one

(2r,4r,6s)-4-hydroxy-2-tridecyl-1,7-dioxadispiro[5.1.5⁸.2⁶]pentadeca-9,12-dien-11-one

C26H42O4 (418.3083)


   

1-(2-hydroxy-6-methylheptan-2-yl)-9a,11a-dimethyl-1h,2h,3h,3ah,3bh,4h,6h,7h,8h,9h,9bh,10h,11h-cyclopenta[a]phenanthrene-2,7-diol

1-(2-hydroxy-6-methylheptan-2-yl)-9a,11a-dimethyl-1h,2h,3h,3ah,3bh,4h,6h,7h,8h,9h,9bh,10h,11h-cyclopenta[a]phenanthrene-2,7-diol

C27H46O3 (418.3447)


   

methyl (12r)-12-[(3-methylbutanoyl)oxy]icosa-5,8,10,14-tetraenoate

methyl (12r)-12-[(3-methylbutanoyl)oxy]icosa-5,8,10,14-tetraenoate

C26H42O4 (418.3083)


   

(5s,7's,9's,15'r,16'r)-5,7',9'-trimethyl-5'-oxaspiro[oxane-2,6'-pentacyclo[10.8.0.0²,⁹.0⁴,⁸.0¹³,¹⁸]icosane]-15',16'-diol

(5s,7's,9's,15'r,16'r)-5,7',9'-trimethyl-5'-oxaspiro[oxane-2,6'-pentacyclo[10.8.0.0²,⁹.0⁴,⁸.0¹³,¹⁸]icosane]-15',16'-diol

C26H42O4 (418.3083)


   

1-(5-hydroxy-6-methylheptan-2-yl)-9a,11a-dimethyl-1h,2h,3bh,4h,5h,5ah,6h,7h,8h,9h,9bh,10h,11h-cyclopenta[a]phenanthrene-5,7-diol

1-(5-hydroxy-6-methylheptan-2-yl)-9a,11a-dimethyl-1h,2h,3bh,4h,5h,5ah,6h,7h,8h,9h,9bh,10h,11h-cyclopenta[a]phenanthrene-5,7-diol

C27H46O3 (418.3447)


   

9a,11a-dimethyl-1-(6-methylheptan-2-yl)-1h,2h,3h,3ah,5h,6h,7h,8h,9h,9bh,10h,11h-cyclopenta[a]phenanthrene-5,5a,7-triol

9a,11a-dimethyl-1-(6-methylheptan-2-yl)-1h,2h,3h,3ah,5h,6h,7h,8h,9h,9bh,10h,11h-cyclopenta[a]phenanthrene-5,5a,7-triol

C27H46O3 (418.3447)


   

(2s)-n-[(5s,6r,7s,10r)-7-isopropyl-2,10-dimethylspiro[4.5]dec-1-en-6-yl]-2-[(2r)-2-(methoxycarbonyl)-5-oxopyrrolidin-1-yl]propanimidic acid

(2s)-n-[(5s,6r,7s,10r)-7-isopropyl-2,10-dimethylspiro[4.5]dec-1-en-6-yl]-2-[(2r)-2-(methoxycarbonyl)-5-oxopyrrolidin-1-yl]propanimidic acid

C24H38N2O4 (418.2831)


   

(2r,4r,6s)-4-hydroxy-2-tridecyl-1,14-dioxadispiro[5.1.5⁸.2⁶]pentadeca-9,12-dien-11-one

(2r,4r,6s)-4-hydroxy-2-tridecyl-1,14-dioxadispiro[5.1.5⁸.2⁶]pentadeca-9,12-dien-11-one

C26H42O4 (418.3083)


   

1,3-dihydroxypropan-2-yl 3,6-dihydroxyicosanoate

1,3-dihydroxypropan-2-yl 3,6-dihydroxyicosanoate

C23H46O6 (418.3294)


   

19-(2h-1,3-benzodioxol-5-yl)nonadecanoic acid

19-(2h-1,3-benzodioxol-5-yl)nonadecanoic acid

C26H42O4 (418.3083)


   

1-(4-hydroxy-6-methylheptan-2-yl)-9a,11a-dimethyl-1h,2h,3h,3ah,3bh,4h,5h,5ah,6h,7h,8h,9h,11h-cyclopenta[a]phenanthrene-5,7-diol

1-(4-hydroxy-6-methylheptan-2-yl)-9a,11a-dimethyl-1h,2h,3h,3ah,3bh,4h,5h,5ah,6h,7h,8h,9h,11h-cyclopenta[a]phenanthrene-5,7-diol

C27H46O3 (418.3447)


   

(2e)-3-(4-hydroxy-3-methoxyphenyl)prop-2-en-1-yl hexadecanoate

(2e)-3-(4-hydroxy-3-methoxyphenyl)prop-2-en-1-yl hexadecanoate

C26H42O4 (418.3083)


   

n-({[(2r,4ar,7r,8as,10as)-7-ethenyl-1,1,4a,7-tetramethyl-3,4,6,8,8a,9,10,10a-octahydro-2h-phenanthren-2-yl]oxy}(hydroxy)methylidene)-2-hydroxyethanecarbamimidic acid

n-({[(2r,4ar,7r,8as,10as)-7-ethenyl-1,1,4a,7-tetramethyl-3,4,6,8,8a,9,10,10a-octahydro-2h-phenanthren-2-yl]oxy}(hydroxy)methylidene)-2-hydroxyethanecarbamimidic acid

C24H38N2O4 (418.2831)


   

2-isopropyl-10-[(4-isopropylphenyl)methyl]-4b,8,8-trimethyl-5,6,7,8a,9,10-hexahydrophenanthren-3-ol

2-isopropyl-10-[(4-isopropylphenyl)methyl]-4b,8,8-trimethyl-5,6,7,8a,9,10-hexahydrophenanthren-3-ol

C30H42O (418.3235)


   

6-{7-hydroxy-9a,11a-dimethyl-1h,2h,3h,3ah,3bh,4h,6h,7h,8h,9h,9bh,10h,11h-cyclopenta[a]phenanthren-1-yl}-2-methylheptane-1,5-diol

6-{7-hydroxy-9a,11a-dimethyl-1h,2h,3h,3ah,3bh,4h,6h,7h,8h,9h,9bh,10h,11h-cyclopenta[a]phenanthren-1-yl}-2-methylheptane-1,5-diol

C27H46O3 (418.3447)


   

1,3-dihydroxypropan-2-yl 3,8-dihydroxyicosanoate

1,3-dihydroxypropan-2-yl 3,8-dihydroxyicosanoate

C23H46O6 (418.3294)


   

1,3-dihydroxypropan-2-yl (3r,7r)-3,7-dihydroxyicosanoate

1,3-dihydroxypropan-2-yl (3r,7r)-3,7-dihydroxyicosanoate

C23H46O6 (418.3294)


   

(2r,4r,6r)-4-hydroxy-2-tridecyl-1,7-dioxadispiro[5.1.5⁸.2⁶]pentadeca-9,12-dien-11-one

(2r,4r,6r)-4-hydroxy-2-tridecyl-1,7-dioxadispiro[5.1.5⁸.2⁶]pentadeca-9,12-dien-11-one

C26H42O4 (418.3083)


   

(2r)-1-(1-{[(5s,6r,7s,10r)-7-isopropyl-2,10-dimethylspiro[4.5]dec-1-en-6-yl]-c-hydroxycarbonimidoyl}-1-methylethyl)-5-oxopyrrolidine-2-carboxylic acid

(2r)-1-(1-{[(5s,6r,7s,10r)-7-isopropyl-2,10-dimethylspiro[4.5]dec-1-en-6-yl]-c-hydroxycarbonimidoyl}-1-methylethyl)-5-oxopyrrolidine-2-carboxylic acid

C24H38N2O4 (418.2831)


   

(1r,3bs,5as,7s,9ar,11ar)-9a,11a-dimethyl-1-[(2r)-6-methylheptan-2-yl]-1h,2h,3h,3ah,6h,7h,8h,9h,9bh,10h,11h-cyclopenta[a]phenanthrene-3b,5a,7-triol

(1r,3bs,5as,7s,9ar,11ar)-9a,11a-dimethyl-1-[(2r)-6-methylheptan-2-yl]-1h,2h,3h,3ah,6h,7h,8h,9h,9bh,10h,11h-cyclopenta[a]phenanthrene-3b,5a,7-triol

C27H46O3 (418.3447)


   

(2r)-n-[(5s,6r,7s,10r)-7-isopropyl-2,10-dimethylspiro[4.5]dec-1-en-6-yl]-2-[(2s)-2-(methoxycarbonyl)-5-oxopyrrolidin-1-yl]propanimidic acid

(2r)-n-[(5s,6r,7s,10r)-7-isopropyl-2,10-dimethylspiro[4.5]dec-1-en-6-yl]-2-[(2s)-2-(methoxycarbonyl)-5-oxopyrrolidin-1-yl]propanimidic acid

C24H38N2O4 (418.2831)


   

(1r,3ar,5r,5ar,7s,9ar,9bs,11ar)-9a,11a-dimethyl-1-[(2r)-6-methylheptan-2-yl]-1h,2h,3h,3ah,5h,6h,7h,8h,9h,9bh,10h,11h-cyclopenta[a]phenanthrene-5,5a,7-triol

(1r,3ar,5r,5ar,7s,9ar,9bs,11ar)-9a,11a-dimethyl-1-[(2r)-6-methylheptan-2-yl]-1h,2h,3h,3ah,5h,6h,7h,8h,9h,9bh,10h,11h-cyclopenta[a]phenanthrene-5,5a,7-triol

C27H46O3 (418.3447)


   

6-hydroxy-2-[2-(2-hydroxyethyl)-2-methyl-3-(6-methylheptan-2-yl)cyclopentyl]-8a-methyl-2,3,5,6,7,8-hexahydronaphthalen-1-one

6-hydroxy-2-[2-(2-hydroxyethyl)-2-methyl-3-(6-methylheptan-2-yl)cyclopentyl]-8a-methyl-2,3,5,6,7,8-hexahydronaphthalen-1-one

C27H46O3 (418.3447)


   

8'-apo-β-carotenol

8'-apo-β-carotenol

C30H42O (418.3235)


   

1-(3-hydroxy-6-methylheptan-2-yl)-9a,11a-dimethyl-1h,2h,3h,3ah,3bh,4h,6h,7h,8h,9h,9bh,10h,11h-cyclopenta[a]phenanthrene-6,7-diol

1-(3-hydroxy-6-methylheptan-2-yl)-9a,11a-dimethyl-1h,2h,3h,3ah,3bh,4h,6h,7h,8h,9h,9bh,10h,11h-cyclopenta[a]phenanthrene-6,7-diol

C27H46O3 (418.3447)


   

1,3-dihydroxypropan-2-yl (3r,9r)-3,9-dihydroxyicosanoate

1,3-dihydroxypropan-2-yl (3r,9r)-3,9-dihydroxyicosanoate

C23H46O6 (418.3294)


   

(1r,3as,3bs,4r,7s,9ar,9bs,11ar)-4-hydroperoxy-9a,11a-dimethyl-1-[(2r)-6-methylheptan-2-yl]-1h,2h,3h,3ah,3bh,4h,6h,7h,8h,9h,9bh,10h,11h-cyclopenta[a]phenanthren-7-ol

(1r,3as,3bs,4r,7s,9ar,9bs,11ar)-4-hydroperoxy-9a,11a-dimethyl-1-[(2r)-6-methylheptan-2-yl]-1h,2h,3h,3ah,3bh,4h,6h,7h,8h,9h,9bh,10h,11h-cyclopenta[a]phenanthren-7-ol

C27H46O3 (418.3447)


   

hexadecyl 3-(2-hydroxy-4-methoxyphenyl)prop-2-enoate

hexadecyl 3-(2-hydroxy-4-methoxyphenyl)prop-2-enoate

C26H42O4 (418.3083)


   

4-hydroxy-5-(2-hydroxy-2-methyl-14-phenyltetradecyl)-5-methyloxolan-2-one

4-hydroxy-5-(2-hydroxy-2-methyl-14-phenyltetradecyl)-5-methyloxolan-2-one

C26H42O4 (418.3083)


   

(2s,4s,6r)-4-hydroxy-2-tridecyl-1,7-dioxadispiro[5.1.5⁸.2⁶]pentadeca-9,12-dien-11-one

(2s,4s,6r)-4-hydroxy-2-tridecyl-1,7-dioxadispiro[5.1.5⁸.2⁶]pentadeca-9,12-dien-11-one

C26H42O4 (418.3083)


   

2,16-dimethyl-15-(6-methylheptan-2-yl)-8-oxapentacyclo[9.7.0.0²,⁷.0⁷,⁹.0¹²,¹⁶]octadecane-5,10-diol

2,16-dimethyl-15-(6-methylheptan-2-yl)-8-oxapentacyclo[9.7.0.0²,⁷.0⁷,⁹.0¹²,¹⁶]octadecane-5,10-diol

C27H46O3 (418.3447)


   

(1r,3as,3bs,4s,7s,9ar,9bs,11ar)-4-hydroperoxy-9a,11a-dimethyl-1-[(2r)-6-methylheptan-2-yl]-1h,2h,3h,3ah,3bh,4h,6h,7h,8h,9h,9bh,10h,11h-cyclopenta[a]phenanthren-7-ol

(1r,3as,3bs,4s,7s,9ar,9bs,11ar)-4-hydroperoxy-9a,11a-dimethyl-1-[(2r)-6-methylheptan-2-yl]-1h,2h,3h,3ah,3bh,4h,6h,7h,8h,9h,9bh,10h,11h-cyclopenta[a]phenanthren-7-ol

C27H46O3 (418.3447)


   

8,11,12,13,15,16-hexahydroxy-4,8,12,16-tetramethyloctadec-5-en-7-one

8,11,12,13,15,16-hexahydroxy-4,8,12,16-tetramethyloctadec-5-en-7-one

C22H42O7 (418.293)


   

aculeatin a

aculeatin a

C26H42O4 (418.3083)


   

hentriacontanonaene

hentriacontanonaene

C31H46 (418.3599)


   

(1s,4s,6r,9s,10s,13r,14r)-14-(hydroxymethyl)-14-methoxy-5,5,9-trimethyltetracyclo[11.2.1.0¹,¹⁰.0⁴,⁹]hexadecan-6-yl (2z)-2-methylbut-2-enoate

(1s,4s,6r,9s,10s,13r,14r)-14-(hydroxymethyl)-14-methoxy-5,5,9-trimethyltetracyclo[11.2.1.0¹,¹⁰.0⁴,⁹]hexadecan-6-yl (2z)-2-methylbut-2-enoate

C26H42O4 (418.3083)


   

(1'r,2r,2's,3's,4'r,5r,8's,9'r,12's,13's,16's,18's)-5,9',13'-trimethyl-5'-oxaspiro[oxane-2,6'-pentacyclo[10.8.0.0²,⁹.0⁴,⁸.0¹³,¹⁸]icosane]-3',16'-diol

(1'r,2r,2's,3's,4'r,5r,8's,9'r,12's,13's,16's,18's)-5,9',13'-trimethyl-5'-oxaspiro[oxane-2,6'-pentacyclo[10.8.0.0²,⁹.0⁴,⁸.0¹³,¹⁸]icosane]-3',16'-diol

C26H42O4 (418.3083)


   

(1r,3as,3bs,4r,7s,9as,9bs,11ar)-9a-(hydroxymethyl)-11a-methyl-1-[(2r)-6-methylheptan-2-yl]-1h,2h,3h,3ah,3bh,4h,6h,7h,8h,9h,9bh,10h,11h-cyclopenta[a]phenanthrene-4,7-diol

(1r,3as,3bs,4r,7s,9as,9bs,11ar)-9a-(hydroxymethyl)-11a-methyl-1-[(2r)-6-methylheptan-2-yl]-1h,2h,3h,3ah,3bh,4h,6h,7h,8h,9h,9bh,10h,11h-cyclopenta[a]phenanthrene-4,7-diol

C27H46O3 (418.3447)


   

[6-(2,6-dimethyl-10-phenyldecyl)-4,6-dimethyl-1,2-dioxan-3-yl]acetic acid

[6-(2,6-dimethyl-10-phenyldecyl)-4,6-dimethyl-1,2-dioxan-3-yl]acetic acid

C26H42O4 (418.3083)


   

n-({[(2r,4ar,7r,8as)-7-ethenyl-1,1,4a,7-tetramethyl-3,4,6,8,8a,9,10,10a-octahydro-2h-phenanthren-2-yl]oxy}(hydroxy)methylidene)-2-hydroxyethanecarbamimidic acid

n-({[(2r,4ar,7r,8as)-7-ethenyl-1,1,4a,7-tetramethyl-3,4,6,8,8a,9,10,10a-octahydro-2h-phenanthren-2-yl]oxy}(hydroxy)methylidene)-2-hydroxyethanecarbamimidic acid

C24H38N2O4 (418.2831)


   

methyl (5z,8z,10e,12r,14z)-12-[(3-methylbutanoyl)oxy]icosa-5,8,10,14-tetraenoate

methyl (5z,8z,10e,12r,14z)-12-[(3-methylbutanoyl)oxy]icosa-5,8,10,14-tetraenoate

C26H42O4 (418.3083)


   

2,6,10,14,19,23-hexamethyltetracosa-4,6,8,10,12,14,16,18,20,22-decaen-2-ol

2,6,10,14,19,23-hexamethyltetracosa-4,6,8,10,12,14,16,18,20,22-decaen-2-ol

C30H42O (418.3235)


   

1-(3-hydroxy-6-methylheptan-2-yl)-9a,11a-dimethyl-1h,2h,3h,3ah,3bh,4h,6h,7h,8h,9h,9bh,10h,11h-cyclopenta[a]phenanthrene-2,7-diol

1-(3-hydroxy-6-methylheptan-2-yl)-9a,11a-dimethyl-1h,2h,3h,3ah,3bh,4h,6h,7h,8h,9h,9bh,10h,11h-cyclopenta[a]phenanthrene-2,7-diol

C27H46O3 (418.3447)


   

4-hydroperoxy-9a,11a-dimethyl-1-(6-methylheptan-2-yl)-1h,2h,3h,3ah,3bh,4h,6h,7h,8h,9h,9bh,10h,11h-cyclopenta[a]phenanthren-7-ol

4-hydroperoxy-9a,11a-dimethyl-1-(6-methylheptan-2-yl)-1h,2h,3h,3ah,3bh,4h,6h,7h,8h,9h,9bh,10h,11h-cyclopenta[a]phenanthren-7-ol

C27H46O3 (418.3447)


   

2,6,10,15,19,23-hexamethyltetracosa-2,4,6,8,10,12,14,16,18,22-decaen-1-ol

2,6,10,15,19,23-hexamethyltetracosa-2,4,6,8,10,12,14,16,18,22-decaen-1-ol

C30H42O (418.3235)


   

(1r,2r,3as,3bs,7s,9ar,9bs,11as)-1-[(2s,3s)-3-hydroxy-6-methylheptan-2-yl]-9a,11a-dimethyl-1h,2h,3h,3ah,3bh,4h,6h,7h,8h,9h,9bh,10h,11h-cyclopenta[a]phenanthrene-2,7-diol

(1r,2r,3as,3bs,7s,9ar,9bs,11as)-1-[(2s,3s)-3-hydroxy-6-methylheptan-2-yl]-9a,11a-dimethyl-1h,2h,3h,3ah,3bh,4h,6h,7h,8h,9h,9bh,10h,11h-cyclopenta[a]phenanthrene-2,7-diol

C27H46O3 (418.3447)


   

9a,11a-dimethyl-1-(6-methylheptan-2-yl)-1h,2h,3h,3ah,6h,7h,8h,9h,9bh,10h,11h-cyclopenta[a]phenanthrene-3b,5a,7-triol

9a,11a-dimethyl-1-(6-methylheptan-2-yl)-1h,2h,3h,3ah,6h,7h,8h,9h,9bh,10h,11h-cyclopenta[a]phenanthrene-3b,5a,7-triol

C27H46O3 (418.3447)


   

(4bs,8as,10s)-2-isopropyl-10-[(4-isopropylphenyl)methyl]-4b,8,8-trimethyl-5,6,7,8a,9,10-hexahydrophenanthren-3-ol

(4bs,8as,10s)-2-isopropyl-10-[(4-isopropylphenyl)methyl]-4b,8,8-trimethyl-5,6,7,8a,9,10-hexahydrophenanthren-3-ol

C30H42O (418.3235)